ID

DB08954||

名称

Ifenprodil

描述

N-methyl-D-aspartate (NMDA) receptors (NMDARs) are members of the ionotropic glutamate receptor family, with key roles in brain development and neurological function.[A220118, A220128] NMDARs are heterotetramers that typically involve a dimer of dimers of both GluN1 and GluN2A-D subunits, with each subunit itself composed of an N-terminal domain (NTD), a ligand-binding domain (LBD), a transmembrane domain, and a C-terminal cytoplasmic domain. Binding at the LBD of the agonists glycine (or D-serine) to the GluN1 subunits and of glutamate to the GluN2 subunits is a regulatory mechanism for channel activation. In addition, allosteric modulators are known to bind at the NTDs and form another layer of regulation.[A220118, A220128] One such allosteric regulator is ifenprodil, which was first shown to bind the NMDARs in the 1990s, and specifically to those NMDARs containing the GluN2B subunit.[A220133] Further studies elucidated that ifenprodil binds strongly at the inter-subunit interface of adjacent GluN1 and GluN2B NTDs, where it acts as a non-competitive antagonist.[A220118, A220128] Although ifenprodil has received considerable interest in its potential neuromodulatory activities in psychiatric conditions, including dependency[A220138] and depression,[A220143] it has also been shown to have an immunomodulatory effect.[A220143, A196128] In an unbiased screen for compounds capable of reducing cell death induced by infection with the influenza strain H5N1, ifenprodil was found to have a protective effect against H5N1-induced lung damage, in part through its ability to alleviate the H5N1-induced cytokine storm and reduce pulmonary infiltration of neutrophils, natural killer cells, and T cells.[A196128] Ifenprodil is being investigated for its potential utility in treating COVID-19 in an ongoing phase 2b/3 clinical trial (NCT04382924).[L16343]

cas号

23210-56-2

唯一标识码

R8OE3P6O5S

状态

solid

组

investigational,withdrawn,

指示

药效学

作用机制

毒性

代谢

吸收

半衰期

分类

description:This compound belongs to the class of organic compounds known as 4-benzylpiperidines. These are organic compounds containing a benzyl group attached to the 4-position of a piperidine.
direct-parent:4-benzylpiperidines
kingdom:Organic compounds
superclass:Organoheterocyclic compounds
class:Piperidines
subclass:Benzylpiperidines
alternative-parent:1,2-aminoalcohols
alternative-parent:1-hydroxy-2-unsubstituted benzenoids
alternative-parent:Aralkylamines
alternative-parent:Aromatic alcohols
alternative-parent:Azacyclic compounds
alternative-parent:Hydrocarbon derivatives
alternative-parent:Organopnictogen compounds
alternative-parent:Phenylpropanes
alternative-parent:Secondary alcohols
alternative-parent:Trialkylamines
substituent:1,2-aminoalcohol
substituent:1-hydroxy-2-unsubstituted benzenoid
substituent:4-benzylpiperidine
substituent:Alcohol
substituent:Amine
substituent:Aralkylamine
substituent:Aromatic alcohol
substituent:Aromatic heteromonocyclic compound
substituent:Azacycle
substituent:Benzenoid
substituent:Hydrocarbon derivative
substituent:Monocyclic benzene moiety
substituent:Organic nitrogen compound
substituent:Organic oxygen compound
substituent:Organonitrogen compound
substituent:Organooxygen compound
substituent:Organopnictogen compound
substituent:Phenol
substituent:Phenylpropane
substituent:Secondary alcohol
substituent:Tertiary aliphatic amine
substituent:Tertiary amine

消除途径

种类

Adrenergic Agents
D018663
Adrenergic alpha-Antagonists
D000317
Adrenergic Antagonists
D018674
Agents that produce hypertension

Anti-Parkinson Drugs
D000978
Anticonvulsants
D000927
Cardiovascular Agents
D002317
Central Nervous System Depressants
D002492
Excitatory Amino Acid Agents
D018683
Excitatory Amino Acid Antagonists
D018691
Experimental Unapproved Treatments for COVID-19

Neurotransmitter Agents
D018377
NMDA Receptor Antagonists

Peripheral Vasodilators

Receptors, N-Methyl-D-Aspartate
D016194
Vasodilating Agents
D014665

盐类

DBSALT001078Ifenprodil tartrate89CTB4XUF723210-58-4DMPRDSPPYMZQBT-CEAXSRTFSA-N800.99800.42479614

蛋白质结合

清除

同义词

language:english; code:inn/dcf; name;Ifenprodil
language:latin; code:inn; name;Ifenprodilum

国际品牌

CerocralSanofiFurezanilTsuruhara SeiyakuIburonolTowa YakuhinLinbulaneTatsumi KagakuTechnisSawai SeiyakuVadilexSanofiVasculodilKyowa YakuhinYouajylYoshindo

配送量

产品

混合物

包装者

生产者

价格

受影响的生物体

剂量

atc代码

Other peripheral vasodilators
PERIPHERAL VASODILATORS
PERIPHERAL VASODILATORS
CARDIOVASCULAR SYSTEM

fda标签

化学品安全技术说明书

专利

食物相互作用

药物相互作用

DB00177
Ifenprodil may decrease the antihypertensive activities of Valsartan.
DB00178
Ifenprodil may decrease the antihypertensive activities of Ramipril.
DB00187
Ifenprodil may decrease the antihypertensive activities of Esmolol.
DB00195
Ifenprodil may decrease the antihypertensive activities of Betaxolol.
DB00212
Ifenprodil may decrease the antihypertensive activities of Remikiren.
DB00214
Ifenprodil may decrease the antihypertensive activities of Torasemide.
DB00226
Ifenprodil may decrease the antihypertensive activities of Guanadrel.
DB00264
Ifenprodil may decrease the antihypertensive activities of Metoprolol.
DB00270
Ifenprodil may decrease the antihypertensive activities of Isradipine.
DB00275
Ifenprodil may decrease the antihypertensive activities of Olmesartan.
DB00310
Ifenprodil may decrease the antihypertensive activities of Chlorthalidone.
DB00325
Ifenprodil may decrease the antihypertensive activities of Nitroprusside.
DB00335
Ifenprodil may decrease the antihypertensive activities of Atenolol.
DB00343
Ifenprodil may decrease the antihypertensive activities of Diltiazem.
DB00350
Ifenprodil may decrease the antihypertensive activities of Minoxidil.
DB00373
Ifenprodil may decrease the antihypertensive activities of Timolol.
DB00374
Ifenprodil may decrease the antihypertensive activities of Treprostinil.
DB00381
Ifenprodil may decrease the antihypertensive activities of Amlodipine.
DB00393
Ifenprodil may decrease the antihypertensive activities of Nimodipine.
DB00401
Ifenprodil may decrease the antihypertensive activities of Nisoldipine.
DB00436
Ifenprodil may decrease the antihypertensive activities of Bendroflumethiazide.
DB00457
Ifenprodil may decrease the antihypertensive activities of Prazosin.
DB00492
Ifenprodil may decrease the antihypertensive activities of Fosinopril.
DB00519
Ifenprodil may decrease the antihypertensive activities of Trandolapril.
DB00524
Ifenprodil may decrease the antihypertensive activities of Metolazone.
DB00528
Ifenprodil may decrease the antihypertensive activities of Lercanidipine.
DB00542
Ifenprodil may decrease the antihypertensive activities of Benazepril.
DB00559
Ifenprodil may decrease the antihypertensive activities of Bosentan.
DB00571
Ifenprodil may decrease the antihypertensive activities of Propranolol.
DB00584
Ifenprodil may decrease the antihypertensive activities of Enalapril.
DB00590
Ifenprodil may decrease the antihypertensive activities of Doxazosin.
DB00598
Ifenprodil may decrease the antihypertensive activities of Labetalol.
DB00606
Ifenprodil may decrease the antihypertensive activities of Cyclothiazide.
DB00612
Ifenprodil may decrease the antihypertensive activities of Bisoprolol.
DB00616
Ifenprodil may decrease the antihypertensive activities of Candoxatril.
DB00657
Ifenprodil may decrease the antihypertensive activities of Mecamylamine.
DB00678
Ifenprodil may decrease the antihypertensive activities of Losartan.
DB00691
Ifenprodil may decrease the antihypertensive activities of Moexipril.
DB00700
Ifenprodil may decrease the antihypertensive activities of Eplerenone.
DB00722
Ifenprodil may decrease the antihypertensive activities of Lisinopril.
DB00727
Ifenprodil may decrease the antihypertensive activities of Nitroglycerin.
DB00774
Ifenprodil may decrease the antihypertensive activities of Hydroflumethiazide.
DB00785
Ifenprodil may decrease the antihypertensive activities of Cryptenamine.
DB00790
Ifenprodil may decrease the antihypertensive activities of Perindopril.
DB00796
Ifenprodil may decrease the antihypertensive activities of Candesartan cilexetil.
DB00800
Ifenprodil may decrease the antihypertensive activities of Fenoldopam.
DB00808
Ifenprodil may decrease the antihypertensive activities of Indapamide.
DB00820
Ifenprodil may decrease the antihypertensive activities of Tadalafil.
DB00876
Ifenprodil may decrease the antihypertensive activities of Eprosartan.
DB00880
Ifenprodil may decrease the antihypertensive activities of Chlorothiazide.
DB00881
Ifenprodil may decrease the antihypertensive activities of Quinapril.
DB00966
Ifenprodil may decrease the antihypertensive activities of Telmisartan.
DB00968
Ifenprodil may decrease the antihypertensive activities of Methyldopa.
DB00999
Ifenprodil may decrease the antihypertensive activities of Hydrochlorothiazide.
DB01021
Ifenprodil may decrease the antihypertensive activities of Trichlormethiazide.
DB01023
Ifenprodil may decrease the antihypertensive activities of Felodipine.
DB01029
Ifenprodil may decrease the antihypertensive activities of Irbesartan.
DB01054
Ifenprodil may decrease the antihypertensive activities of Nitrendipine.
DB01089
Ifenprodil may decrease the antihypertensive activities of Deserpidine.
DB01090
Ifenprodil may decrease the antihypertensive activities of Pentolinium.
DB01116
Ifenprodil may decrease the antihypertensive activities of Trimethaphan.
DB01119
Ifenprodil may decrease the antihypertensive activities of Diazoxide.
DB01136
Ifenprodil may decrease the antihypertensive activities of Carvedilol.
DB01158
Ifenprodil may decrease the antihypertensive activities of Bretylium.
DB01162
Ifenprodil may decrease the antihypertensive activities of Terazosin.
DB01170
Ifenprodil may decrease the antihypertensive activities of Guanethidine.
DB01193
Ifenprodil may decrease the antihypertensive activities of Acebutolol.
DB01197
Ifenprodil may decrease the antihypertensive activities of Captopril.
DB01203
Ifenprodil may decrease the antihypertensive activities of Nadolol.
DB01240
Ifenprodil may decrease the antihypertensive activities of Epoprostenol.
DB01244
Ifenprodil may decrease the antihypertensive activities of Bepridil.
DB01275
Ifenprodil may decrease the antihypertensive activities of Hydralazine.
DB01295
Ifenprodil may decrease the antihypertensive activities of Bevantolol.
DB01297
Ifenprodil may decrease the antihypertensive activities of Practolol.
DB01324
Ifenprodil may decrease the antihypertensive activities of Polythiazide.
DB01340
Ifenprodil may decrease the antihypertensive activities of Cilazapril.
DB01347
Ifenprodil may decrease the antihypertensive activities of Saprisartan.
DB01348
Ifenprodil may decrease the antihypertensive activities of Spirapril.
DB01388
Ifenprodil may decrease the antihypertensive activities of Mibefradil.
DB03322
Ifenprodil may decrease the antihypertensive activities of Dexpropranolol.
DB04831
Ifenprodil may decrease the antihypertensive activities of Tienilic acid.
DB04840
Ifenprodil may decrease the antihypertensive activities of Debrisoquine.
DB04846
Ifenprodil may decrease the antihypertensive activities of Celiprolol.
DB04861
Ifenprodil may decrease the antihypertensive activities of Nebivolol.
DB06268
Ifenprodil may decrease the antihypertensive activities of Sitaxentan.
DB06403
Ifenprodil may decrease the antihypertensive activities of Ambrisentan.
DB06445
Ifenprodil may decrease the antihypertensive activities of Diethylnorspermine.
DB06712
Ifenprodil may decrease the antihypertensive activities of Nilvadipine.
DB06762
Ifenprodil may decrease the antihypertensive activities of Pinacidil.
DB07767
Ifenprodil may decrease the antihypertensive activities of Ferulic acid.
DB08808
Ifenprodil may decrease the antihypertensive activities of Bupranolol.
DB08836
Ifenprodil may decrease the antihypertensive activities of Temocapril.
DB08931
Ifenprodil may decrease the antihypertensive activities of Riociguat.
DB08932
Ifenprodil may decrease the antihypertensive activities of Macitentan.
DB08952
Ifenprodil may decrease the antihypertensive activities of Indenolol.
DB09026
Ifenprodil may decrease the antihypertensive activities of Aliskiren.
DB09206
Ifenprodil may decrease the antihypertensive activities of Trimazosin.
DB09220
Ifenprodil may decrease the antihypertensive activities of Nicorandil.
DB09235
Ifenprodil may decrease the antihypertensive activities of Efonidipine.
DB09236
Ifenprodil may decrease the antihypertensive activities of Lacidipine.
DB09238
Ifenprodil may decrease the antihypertensive activities of Manidipine.
DB09239
Ifenprodil may decrease the antihypertensive activities of Niguldipine.
DB09363
Ifenprodil may decrease the antihypertensive activities of Rauwolfia serpentina root.
DB09477
Ifenprodil may decrease the antihypertensive activities of Enalaprilat.
DB11362
Ifenprodil may decrease the antihypertensive activities of Selexipag.
DB11720
Ifenprodil may decrease the antihypertensive activities of Angiotensin 1-7.
DB11770
Ifenprodil may decrease the antihypertensive activities of Talinolol.
DB11783
Ifenprodil may decrease the antihypertensive activities of Imidapril.
DB12054
Ifenprodil may decrease the antihypertensive activities of BQ-123.
DB12212
Ifenprodil may decrease the antihypertensive activities of Landiolol.
DB12766
Ifenprodil may decrease the antihypertensive activities of Cicletanine.
DB12945
Ifenprodil may decrease the antihypertensive activities of Dihydralazine.
DB13166
Ifenprodil may decrease the antihypertensive activities of Zofenopril.
DB13211
Ifenprodil may decrease the antihypertensive activities of Guanoxan.
DB13312
Ifenprodil may decrease the antihypertensive activities of Delapril.
DB13374
Ifenprodil may decrease the antihypertensive activities of Vincamine.
DB13400
Ifenprodil may decrease the antihypertensive activities of Linsidomine.
DB13410
Ifenprodil may decrease the antihypertensive activities of Guanoxabenz.
DB13429
Ifenprodil may decrease the antihypertensive activities of Tolonidine.
DB13435
Ifenprodil may decrease the antihypertensive activities of Endralazine.
DB13443
Ifenprodil may decrease the antihypertensive activities of Esatenolol.
DB13452
Ifenprodil may decrease the antihypertensive activities of Cadralazine.
DB13508
Ifenprodil may decrease the antihypertensive activities of Cloranolol.
DB13532
Ifenprodil may decrease the antihypertensive activities of Cyclopenthiazide.
DB13575
Ifenprodil may decrease the antihypertensive activities of Bietaserpine.
DB13604
Ifenprodil may decrease the antihypertensive activities of Guanazodine.
DB13631
Ifenprodil may decrease the antihypertensive activities of Methoserpidine.
DB13757
Ifenprodil may decrease the antihypertensive activities of Epanolol.
DB13779
Ifenprodil may decrease the antihypertensive activities of Guanoclor.
DB13801
Ifenprodil may decrease the antihypertensive activities of Muzolimine.
DB13803
Ifenprodil may decrease the antihypertensive activities of Xipamide.
DB13919
Ifenprodil may decrease the antihypertensive activities of Candesartan.
DB14068
Ifenprodil may decrease the antihypertensive activities of Dexniguldipine.
DB14094
Ifenprodil may decrease the antihypertensive activities of Tocopherylquinone.
DB14125
Ifenprodil may decrease the antihypertensive activities of Benazeprilat.
DB14207
Ifenprodil may decrease the antihypertensive activities of Fosinoprilat.
DB14208
Ifenprodil may decrease the antihypertensive activities of Ramiprilat.
DB14213
Ifenprodil may decrease the antihypertensive activities of Perindoprilat.
DB14217
Ifenprodil may decrease the antihypertensive activities of Quinaprilat.
DB00695
Ifenprodil may decrease the antihypertensive activities of Furosemide.
DB09237
Ifenprodil may decrease the antihypertensive activities of Levamlodipine.
DB00921
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
DB00366
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ifenprodil.
DB00470
Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Ifenprodil.
DB00450
Droperidol may increase the central nervous system depressant (CNS depressant) activities of Ifenprodil.
DB00956
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
DB00557
Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ifenprodil.
DB00653
The therapeutic efficacy of Ifenprodil can be increased when used in combination with Magnesium sulfate.
DB01403
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
DB00765
Ifenprodil may increase the sedative activities of Metyrosine.
DB01017
Minocycline may increase the central nervous system depressant (CNS depressant) activities of Ifenprodil.
DB00370
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
DB00486
Nabilone may increase the central nervous system depressant (CNS depressant) activities of Ifenprodil.
DB01173
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
DB09117
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
DB08883
Perampanel may increase the central nervous system depressant (CNS depressant) activities of Ifenprodil.
DB00413
Ifenprodil may increase the sedative activities of Pramipexole.
DB00268
Ifenprodil may increase the sedative activities of Ropinirole.
DB05271
Ifenprodil may increase the sedative activities of Rotigotine.
DB06201
The risk or severity of adverse effects can be increased when Rufinamide is combined with Ifenprodil.
DB09072
Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Ifenprodil.
DB09034
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
DB06204
Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Ifenprodil.
DB01041
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
DB00425
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
DB00035
The risk or severity of hypertension can be increased when Desmopressin is combined with Ifenprodil.
DB00159
The risk or severity of hypertension can be increased when Icosapent is combined with Ifenprodil.
DB00211
The risk or severity of hypertension can be increased when Midodrine is combined with Ifenprodil.
DB00217
The risk or severity of hypertension can be increased when Bethanidine is combined with Ifenprodil.
DB00221
The risk or severity of hypertension can be increased when Isoetharine is combined with Ifenprodil.
DB00244
The risk or severity of hypertension can be increased when Mesalazine is combined with Ifenprodil.
DB00328
The risk or severity of hypertension can be increased when Indomethacin is combined with Ifenprodil.
DB00353
The risk or severity of hypertension can be increased when Methylergometrine is combined with Ifenprodil.
DB00388
The risk or severity of hypertension can be increased when Phenylephrine is combined with Ifenprodil.
DB00461
The risk or severity of hypertension can be increased when Nabumetone is combined with Ifenprodil.
DB00465
The risk or severity of hypertension can be increased when Ketorolac is combined with Ifenprodil.
DB00469
The risk or severity of hypertension can be increased when Tenoxicam is combined with Ifenprodil.
DB00482
The risk or severity of hypertension can be increased when Celecoxib is combined with Ifenprodil.
DB00490
The risk or severity of hypertension can be increased when Buspirone is combined with Ifenprodil.
DB00500
The risk or severity of hypertension can be increased when Tolmetin is combined with Ifenprodil.
DB00533
The risk or severity of hypertension can be increased when Rofecoxib is combined with Ifenprodil.
DB00554
The risk or severity of hypertension can be increased when Piroxicam is combined with Ifenprodil.
DB00561
The risk or severity of hypertension can be increased when Doxapram is combined with Ifenprodil.
DB00573
The risk or severity of hypertension can be increased when Fenoprofen is combined with Ifenprodil.
DB00580
The risk or severity of hypertension can be increased when Valdecoxib is combined with Ifenprodil.
DB00586
The risk or severity of hypertension can be increased when Diclofenac is combined with Ifenprodil.
DB00605
The risk or severity of hypertension can be increased when Sulindac is combined with Ifenprodil.
DB00610
The risk or severity of hypertension can be increased when Metaraminol is combined with Ifenprodil.
DB00629
The risk or severity of hypertension can be increased when Guanabenz is combined with Ifenprodil.
DB00692
The risk or severity of hypertension can be increased when Phentolamine is combined with Ifenprodil.
DB00699
The risk or severity of hypertension can be increased when Nicergoline is combined with Ifenprodil.
DB00712
The risk or severity of hypertension can be increased when Flurbiprofen is combined with Ifenprodil.
DB00723
The risk or severity of hypertension can be increased when Methoxamine is combined with Ifenprodil.
DB00749
The risk or severity of hypertension can be increased when Etodolac is combined with Ifenprodil.
DB00784
The risk or severity of hypertension can be increased when Mefenamic acid is combined with Ifenprodil.
DB00788
The risk or severity of hypertension can be increased when Naproxen is combined with Ifenprodil.
DB00795
The risk or severity of hypertension can be increased when Sulfasalazine is combined with Ifenprodil.
DB00797
The risk or severity of hypertension can be increased when Tolazoline is combined with Ifenprodil.
DB00812
The risk or severity of hypertension can be increased when Phenylbutazone is combined with Ifenprodil.
DB00814
The risk or severity of hypertension can be increased when Meloxicam is combined with Ifenprodil.
DB00816
The risk or severity of hypertension can be increased when Orciprenaline is combined with Ifenprodil.
DB00821
The risk or severity of hypertension can be increased when Carprofen is combined with Ifenprodil.
DB00830
The risk or severity of hypertension can be increased when Phenmetrazine is combined with Ifenprodil.
DB00841
The risk or severity of hypertension can be increased when Dobutamine is combined with Ifenprodil.
DB00861
The risk or severity of hypertension can be increased when Diflunisal is combined with Ifenprodil.
DB00867
The risk or severity of hypertension can be increased when Ritodrine is combined with Ifenprodil.
DB00871
The risk or severity of hypertension can be increased when Terbutaline is combined with Ifenprodil.
DB00886
The risk or severity of hypertension can be increased when Omapatrilat is combined with Ifenprodil.
DB00901
The risk or severity of hypertension can be increased when Bitolterol is combined with Ifenprodil.
DB00925
The risk or severity of hypertension can be increased when Phenoxybenzamine is combined with Ifenprodil.
DB00935
The risk or severity of hypertension can be increased when Oxymetazoline is combined with Ifenprodil.
DB00936
The risk or severity of hypertension can be increased when Salicylic acid is combined with Ifenprodil.
DB00938
The risk or severity of hypertension can be increased when Salmeterol is combined with Ifenprodil.
DB00939
The risk or severity of hypertension can be increased when Meclofenamic acid is combined with Ifenprodil.
DB00945
The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Ifenprodil.
DB00983
The risk or severity of hypertension can be increased when Formoterol is combined with Ifenprodil.
DB00988
The risk or severity of hypertension can be increased when Dopamine is combined with Ifenprodil.
DB00991
The risk or severity of hypertension can be increased when Oxaprozin is combined with Ifenprodil.
DB01001
The risk or severity of hypertension can be increased when Salbutamol is combined with Ifenprodil.
DB01009
The risk or severity of hypertension can be increased when Ketoprofen is combined with Ifenprodil.
DB01014
The risk or severity of hypertension can be increased when Balsalazide is combined with Ifenprodil.
DB01050
The risk or severity of hypertension can be increased when Ibuprofen is combined with Ifenprodil.
DB01064
The risk or severity of hypertension can be increased when Isoprenaline is combined with Ifenprodil.
DB01102
The risk or severity of hypertension can be increased when Arbutamine is combined with Ifenprodil.
DB01126
The risk or severity of hypertension can be increased when Dutasteride is combined with Ifenprodil.
DB01180
The risk or severity of hypertension can be increased when Rescinnamine is combined with Ifenprodil.
DB01182
The risk or severity of hypertension can be increased when Propafenone is combined with Ifenprodil.
DB01216
The risk or severity of hypertension can be increased when Finasteride is combined with Ifenprodil.
DB01250
The risk or severity of hypertension can be increased when Olsalazine is combined with Ifenprodil.
DB01274
The risk or severity of hypertension can be increased when Arformoterol is combined with Ifenprodil.
DB01283
The risk or severity of hypertension can be increased when Lumiracoxib is combined with Ifenprodil.
DB01288
The risk or severity of hypertension can be increased when Fenoterol is combined with Ifenprodil.
DB01291
The risk or severity of hypertension can be increased when Pirbuterol is combined with Ifenprodil.
DB01363
The risk or severity of hypertension can be increased when Ephedra sinica root is combined with Ifenprodil.
DB01366
The risk or severity of hypertension can be increased when Procaterol is combined with Ifenprodil.
DB01397
The risk or severity of hypertension can be increased when Magnesium salicylate is combined with Ifenprodil.
DB01399
The risk or severity of hypertension can be increased when Salsalate is combined with Ifenprodil.
DB01401
The risk or severity of hypertension can be increased when Choline magnesium trisalicylate is combined with Ifenprodil.
DB01407
The risk or severity of hypertension can be increased when Clenbuterol is combined with Ifenprodil.
DB01408
The risk or severity of hypertension can be increased when Bambuterol is combined with Ifenprodil.
DB01419
The risk or severity of hypertension can be increased when Antrafenine is combined with Ifenprodil.
DB01424
The risk or severity of hypertension can be increased when Aminophenazone is combined with Ifenprodil.
DB01435
The risk or severity of hypertension can be increased when Antipyrine is combined with Ifenprodil.
DB01579
The risk or severity of hypertension can be increased when Phendimetrazine is combined with Ifenprodil.
DB01600
The risk or severity of hypertension can be increased when Tiaprofenic acid is combined with Ifenprodil.
DB01628
The risk or severity of hypertension can be increased when Etoricoxib is combined with Ifenprodil.
DB02032
The risk or severity of hypertension can be increased when Epicaptopril is combined with Ifenprodil.
DB02224
The risk or severity of hypertension can be increased when Taxifolin is combined with Ifenprodil.
DB03585
The risk or severity of hypertension can be increased when Oxyphenbutazone is combined with Ifenprodil.
DB04581
The risk or severity of hypertension can be increased when 1-benzylimidazole is combined with Ifenprodil.
DB04743
The risk or severity of hypertension can be increased when Nimesulide is combined with Ifenprodil.
DB04812
The risk or severity of hypertension can be increased when Benoxaprofen is combined with Ifenprodil.
DB04817
The risk or severity of hypertension can be increased when Metamizole is combined with Ifenprodil.
DB04828
The risk or severity of hypertension can be increased when Zomepirac is combined with Ifenprodil.
DB04855
The risk or severity of hypertension can be increased when Dronedarone is combined with Ifenprodil.
DB05039
The risk or severity of hypertension can be increased when Indacaterol is combined with Ifenprodil.
DB05095
The risk or severity of hypertension can be increased when Cimicoxib is combined with Ifenprodil.
DB05395
The risk or severity of hypertension can be increased when Amibegron is combined with Ifenprodil.
DB06152
The risk or severity of hypertension can be increased when Nylidrin is combined with Ifenprodil.
DB06190
The risk or severity of hypertension can be increased when Solabegron is combined with Ifenprodil.
DB06694
The risk or severity of hypertension can be increased when Xylometazoline is combined with Ifenprodil.
DB06706
The risk or severity of hypertension can be increased when Isometheptene is combined with Ifenprodil.
DB06711
The risk or severity of hypertension can be increased when Naphazoline is combined with Ifenprodil.
DB06725
The risk or severity of hypertension can be increased when Lornoxicam is combined with Ifenprodil.
DB06736
The risk or severity of hypertension can be increased when Aceclofenac is combined with Ifenprodil.
DB06737
The risk or severity of hypertension can be increased when Zaltoprofen is combined with Ifenprodil.
DB06763
The risk or severity of hypertension can be increased when Saralasin is combined with Ifenprodil.
DB06764
The risk or severity of hypertension can be increased when Tetryzoline is combined with Ifenprodil.
DB07402
The risk or severity of hypertension can be increased when Azapropazone is combined with Ifenprodil.
DB08439
The risk or severity of hypertension can be increased when Parecoxib is combined with Ifenprodil.
DB08797
The risk or severity of hypertension can be increased when Salicylamide is combined with Ifenprodil.
DB08841
The risk or severity of hypertension can be increased when Tyramine is combined with Ifenprodil.
DB08893
The risk or severity of hypertension can be increased when Mirabegron is combined with Ifenprodil.
DB08925
The risk or severity of hypertension can be increased when Adrafinil is combined with Ifenprodil.
DB08940
The risk or severity of hypertension can be increased when Kebuzone is combined with Ifenprodil.
DB08941
The risk or severity of hypertension can be increased when Isoxsuprine is combined with Ifenprodil.
DB08942
The risk or severity of hypertension can be increased when Isoxicam is combined with Ifenprodil.
DB08950
The risk or severity of hypertension can be increased when Indoramin is combined with Ifenprodil.
DB08951
The risk or severity of hypertension can be increased when Indoprofen is combined with Ifenprodil.
DB08955
The risk or severity of hypertension can be increased when Ifenprodil is combined with Ibuproxam.
DB08957
The risk or severity of hypertension can be increased when Ifenprodil is combined with Hexoprenaline.
DB08976
The risk or severity of hypertension can be increased when Ifenprodil is combined with Floctafenine.
DB08981
The risk or severity of hypertension can be increased when Ifenprodil is combined with Fenbufen.
DB08984
The risk or severity of hypertension can be increased when Ifenprodil is combined with Etofenamate.
DB08985
The risk or severity of hypertension can be increased when Ifenprodil is combined with Etilefrine.
DB08991
The risk or severity of hypertension can be increased when Ifenprodil is combined with Epirizole.
DB09080
The risk or severity of hypertension can be increased when Ifenprodil is combined with Olodaterol.
DB09082
The risk or severity of hypertension can be increased when Ifenprodil is combined with Vilanterol.
DB09084
The risk or severity of hypertension can be increased when Ifenprodil is combined with Benzydamine.
DB09202
The risk or severity of hypertension can be increased when Ifenprodil is combined with Cirazoline.
DB09203
The risk or severity of hypertension can be increased when Ifenprodil is combined with Synephrine.
DB09205
The risk or severity of hypertension can be increased when Ifenprodil is combined with Moxisylyte.
DB09213
The risk or severity of hypertension can be increased when Ifenprodil is combined with Dexibuprofen.
DB09214
The risk or severity of hypertension can be increased when Ifenprodil is combined with Dexketoprofen.
DB09215
The risk or severity of hypertension can be increased when Ifenprodil is combined with Droxicam.
DB09216
The risk or severity of hypertension can be increased when Ifenprodil is combined with Tolfenamic acid.
DB09217
The risk or severity of hypertension can be increased when Ifenprodil is combined with Firocoxib.
DB09218
The risk or severity of hypertension can be increased when Ifenprodil is combined with Clonixin.
DB09242
The risk or severity of hypertension can be increased when Ifenprodil is combined with Moxonidine.
DB09285
The risk or severity of hypertension can be increased when Ifenprodil is combined with Morniflumate.
DB09288
The risk or severity of hypertension can be increased when Ifenprodil is combined with Propacetamol.
DB09295
The risk or severity of hypertension can be increased when Ifenprodil is combined with Talniflumate.
DB11273
The risk or severity of hypertension can be increased when Ifenprodil is combined with Dihydroergocornine.
DB11278
The risk or severity of hypertension can be increased when Ifenprodil is combined with DL-Methylephedrine.
DB11373
The risk or severity of hypertension can be increased when Ifenprodil is combined with Amitraz.
DB11455
The risk or severity of hypertension can be increased when Ifenprodil is combined with Robenacoxib.
DB11466
The risk or severity of hypertension can be increased when Ifenprodil is combined with Tepoxalin.
DB11481
The risk or severity of hypertension can be increased when Ifenprodil is combined with Atipamezole.
DB11518
The risk or severity of hypertension can be increased when Ifenprodil is combined with Flunixin.
DB11541
The risk or severity of hypertension can be increased when Ifenprodil is combined with Ractopamine.
DB11587
The risk or severity of hypertension can be increased when Ifenprodil is combined with Etafedrine.
DB11738
The risk or severity of hypertension can be increased when Ifenprodil is combined with Rilmenidine.
DB11785
The risk or severity of hypertension can be increased when Ifenprodil is combined with Anisodamine.
DB11871
The risk or severity of hypertension can be increased when Ifenprodil is combined with PF-00610355.
DB12092
The risk or severity of hypertension can be increased when Ifenprodil is combined with Naftopidil.
DB12100
The risk or severity of hypertension can be increased when Ifenprodil is combined with Abediterol.
DB12248
The risk or severity of hypertension can be increased when Ifenprodil is combined with Tulobuterol.
DB12313
The risk or severity of hypertension can be increased when Ifenprodil is combined with Dopexamine.
DB12371
The risk or severity of hypertension can be increased when Ifenprodil is combined with Siponimod.
DB12445
The risk or severity of hypertension can be increased when Ifenprodil is combined with Nitroaspirin.
DB12545
The risk or severity of hypertension can be increased when Ifenprodil is combined with Indobufen.
DB12551
The risk or severity of hypertension can be increased when Ifenprodil is combined with Idazoxan.
DB12610
The risk or severity of hypertension can be increased when Ifenprodil is combined with Ebselen.
DB12779
The risk or severity of hypertension can be increased when Ifenprodil is combined with Higenamine.
DB12846
The risk or severity of hypertension can be increased when Ifenprodil is combined with Reproterol.
DB13001
The risk or severity of hypertension can be increased when Ifenprodil is combined with Tinoridine.
DB13064
The risk or severity of hypertension can be increased when Ifenprodil is combined with Tramazoline.
DB13139
The risk or severity of hypertension can be increased when Ifenprodil is combined with Levosalbutamol.
DB13167
The risk or severity of hypertension can be increased when Ifenprodil is combined with Alclofenac.
DB13217
The risk or severity of hypertension can be increased when Ifenprodil is combined with Fentiazac.
DB13232
The risk or severity of hypertension can be increased when Ifenprodil is combined with Suxibuzone.
DB13251
The risk or severity of hypertension can be increased when Ifenprodil is combined with Octopamine.
DB13286
The risk or severity of hypertension can be increased when Ifenprodil is combined with Bumadizone.
DB13314
The risk or severity of hypertension can be increased when Ifenprodil is combined with Alminoprofen.
DB13341
The risk or severity of hypertension can be increased when Ifenprodil is combined with Fenozolone.
DB13345
The risk or severity of hypertension can be increased when Ifenprodil is combined with Dihydroergocristine.
DB13371
The risk or severity of hypertension can be increased when Ifenprodil is combined with Difenpiramide.
DB13378
The risk or severity of hypertension can be increased when Ifenprodil is combined with Norfenefrine.
DB13385
The risk or severity of hypertension can be increased when Ifenprodil is combined with Dihydroergocryptine.
DB13398
The risk or severity of hypertension can be increased when Ifenprodil is combined with Oxyfedrine.
DB13399
The risk or severity of hypertension can be increased when Ifenprodil is combined with Terguride.
DB13407
The risk or severity of hypertension can be increased when Ifenprodil is combined with Nifenazone.
DB13432
The risk or severity of hypertension can be increased when Ifenprodil is combined with Lonazolac.
DB13453
The risk or severity of hypertension can be increased when Ifenprodil is combined with Xenon.
DB13481
The risk or severity of hypertension can be increased when Ifenprodil is combined with Tenidap.
DB13510
The risk or severity of hypertension can be increased when Ifenprodil is combined with Buflomedil.
DB13524
The risk or severity of hypertension can be increased when Ifenprodil is combined with Propyphenazone.
DB13527
The risk or severity of hypertension can be increased when Ifenprodil is combined with Proglumetacin.
DB13538
The risk or severity of hypertension can be increased when Ifenprodil is combined with Guacetisal.
DB13544
The risk or severity of hypertension can be increased when Ifenprodil is combined with Ethenzamide.
DB13559
The risk or severity of hypertension can be increased when Ifenprodil is combined with Rimiterol.
DB13612
The risk or severity of hypertension can be increased when Ifenprodil is combined with Carbaspirin calcium.
DB13629
The risk or severity of hypertension can be increased when Ifenprodil is combined with Mofebutazone.
DB13649
The risk or severity of hypertension can be increased when Ifenprodil is combined with Proquazone.
DB13657
The risk or severity of hypertension can be increased when Ifenprodil is combined with Benorilate.
DB13692
The risk or severity of hypertension can be increased when Ifenprodil is combined with Tretoquinol.
DB13722
The risk or severity of hypertension can be increased when Ifenprodil is combined with Pirprofen.
DB13777
The risk or severity of hypertension can be increased when Ifenprodil is combined with Prenalterol.
DB13781
The risk or severity of hypertension can be increased when Ifenprodil is combined with Xamoterol.
DB13783
The risk or severity of hypertension can be increased when Ifenprodil is combined with Acemetacin.
DB13852
The risk or severity of hypertension can be increased when Ifenprodil is combined with Mefenorex.
DB13860
The risk or severity of hypertension can be increased when Ifenprodil is combined with Imidazole salicylate.
DB14059
The risk or severity of hypertension can be increased when Ifenprodil is combined with SC-236.
DB14060
The risk or severity of hypertension can be increased when Ifenprodil is combined with NS-398.
DB14231
The risk or severity of hypertension can be increased when Ifenprodil is combined with Quinoline Yellow WS.
DB15685
The risk or severity of hypertension can be increased when Ifenprodil is combined with Selpercatinib.
DB09212
The risk or severity of hypertension can be increased when Ifenprodil is combined with Loxoprofen.
DB15965
The risk or severity of hypertension can be increased when Ifenprodil is combined with Naxitamab.
DB00358
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Mefloquine.
DB06148
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Mianserin.
DB01083
Orlistat can cause a decrease in the absorption of Ifenprodil resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB01030
Ifenprodil may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.
DB00422
The risk or severity of adverse effects can be increased when Methylphenidate is combined with Ifenprodil.
DB06701
The risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Ifenprodil.
DB00333
The risk or severity of adverse effects can be increased when Methadone is combined with Ifenprodil.
DB01043
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Memantine.
DB01284
The risk or severity of liver damage can be increased when Tetracosactide is combined with Ifenprodil.
DB00898
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
DB00972
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
DB00484
Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Ifenprodil.
DB00176
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Fluvoxamine.
DB00215
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Citalopram.
DB00476
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Duloxetine.
DB00656
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Trazodone.
DB00715
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Paroxetine.
DB01104
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Sertraline.
DB01105
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Sibutramine.
DB01149
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Nefazodone.
DB01175
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Escitalopram.
DB04832
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Zimelidine.
DB04884
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Dapoxetine.
DB04896
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Milnacipran.
DB06700
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Desvenlafaxine.
DB06731
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Seproxetine.
DB08918
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Levomilnacipran.
DB08953
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Indalpine.
DB12693
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Ritanserin.
DB13233
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Alaproclate.
DB00334
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Olanzapine.
DB00363
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Clozapine.
DB00734
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Risperidone.
DB01224
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Quetiapine.
DB01238
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Aripiprazole.
DB01267
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Paliperidone.
DB04888
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Bifeprunox.
DB04946
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Iloperidone.
DB05316
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Pimavanserin.
DB06016
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Cariprazine.
DB06077
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Lumateperone.
DB06144
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Sertindole.
DB06216
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Asenapine.
DB08815
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Lurasidone.
DB08922
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Perospirone.
DB09128
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Brexpiprazole.
DB09223
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Blonanserin.
DB09224
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Melperone.
DB09225
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Zotepine.
DB09226
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Brilaroxazine.
DB06288
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Amisulpride.
DB00408
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Loxapine.
DB00420
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Promazine.
DB00433
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Prochlorperazine.
DB00477
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Chlorpromazine.
DB00623
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Fluphenazine.
DB00679
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Thioridazine.
DB00831
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Trifluoperazine.
DB00850
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Perphenazine.
DB00875
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Flupentixol.
DB00933
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Mesoridazine.
DB01100
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Pimozide.
DB01239
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Chlorprothixene.
DB01608
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Periciazine.
DB01618
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Molindone.
DB01622
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Thioproperazine.
DB01623
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Thiothixene.
DB01624
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Zuclopenthixol.
DB11376
The therapeutic efficacy of Azaperone can be decreased when used in combination with Ifenprodil.
DB00209
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Trospium.
DB00219
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.
DB00245
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Benzatropine.
DB00280
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
DB00321
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.
DB00332
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.
DB00340
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Metixene.
DB00342
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Terfenadine.
DB00354
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Buclizine.
DB00376
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.
DB00383
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.
DB00387
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Procyclidine.
DB00392
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Profenamine.
DB00424
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
DB00434
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.
DB00458
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
DB00462
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine bromide.
DB00496
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Darifenacin.
DB00505
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.
DB00517
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Anisotropine methylbromide.
DB00540
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.
DB00543
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.
DB00572
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Atropine.
DB00622
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Nicardipine.
DB00670
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.
DB00725
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.
DB00767
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Benzquinamide.
DB00777
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Propiomazine.
DB00782
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Propantheline.
DB00804
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.
DB00810
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Biperiden.
DB00907
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Cocaine.
DB00908
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Quinidine.
DB00934
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
DB00940
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Methantheline.
DB00942
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Cycrimine.
DB00986
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.
DB01036
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.
DB01062
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.
DB01142
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Doxepin.
DB01148
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.
DB01151
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Desipramine.
DB01231
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Diphenidol.
DB01409
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Tiotropium.
DB01591
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.
DB01625
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.
DB04843
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.
DB06153
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Pizotifen.
DB06702
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.
DB06787
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.
DB08801
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.
DB08897
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Aclidinium.
DB08997
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Dexetimide.
DB09076
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Umeclidinium.
DB09089
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.
DB09167
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Dosulepin.
DB09262
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Imidafenacin.
DB09300
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.
DB11235
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.
DB11315
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.
DB11855
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Revefenacin.
DB12086
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Oxitropium.
DB12278
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Propiverine.
DB12526
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Batefenterol.
DB12554
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.
DB13252
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Tropatepine.
DB13254
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Prifinium.
DB13351
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.
DB13369
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Benzilone.
DB13380
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Difemerine.
DB13413
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Phenglutarimide.
DB13448
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Mazaticol.
DB13468
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Etybenzatropine.
DB13500
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Otilonium.
DB13507
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Poldine.
DB13542
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Bevonium.
DB13581
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Rociverine.
DB13619
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Bornaprine.
DB13636
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Etanautine.
DB13666
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Tiemonium iodide.
DB13678
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.
DB13695
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Penthienate.
DB13720
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.
DB13738
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Camylofin.
DB13759
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Fenpiverinium.
DB13769
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Emetonium iodide.
DB13844
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.
DB13850
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Timepidium.
DB09007
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.
DB01198
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Zopiclone.
DB00042
The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Ifenprodil.
DB00083
The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ifenprodil.
DB00150
The risk or severity of adverse effects can be increased when Tryptophan is combined with Ifenprodil.
DB00181
The risk or severity of adverse effects can be increased when Baclofen is combined with Ifenprodil.
DB00186
The risk or severity of adverse effects can be increased when Lorazepam is combined with Ifenprodil.
DB00189
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ifenprodil.
DB00202
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Ifenprodil.
DB00206
The risk or severity of adverse effects can be increased when Reserpine is combined with Ifenprodil.
DB00216
The risk or severity of adverse effects can be increased when Eletriptan is combined with Ifenprodil.
DB00228
The risk or severity of adverse effects can be increased when Enflurane is combined with Ifenprodil.
DB00231
The risk or severity of adverse effects can be increased when Temazepam is combined with Ifenprodil.
DB00234
The risk or severity of adverse effects can be increased when Reboxetine is combined with Ifenprodil.
DB00237
The risk or severity of adverse effects can be increased when Butabarbital is combined with Ifenprodil.
DB00241
The risk or severity of adverse effects can be increased when Butalbital is combined with Ifenprodil.
DB00247
The risk or severity of adverse effects can be increased when Methysergide is combined with Ifenprodil.
DB00248
The risk or severity of adverse effects can be increased when Cabergoline is combined with Ifenprodil.
DB00252
The risk or severity of adverse effects can be increased when Phenytoin is combined with Ifenprodil.
DB00273
The risk or severity of adverse effects can be increased when Topiramate is combined with Ifenprodil.
DB00283
The risk or severity of adverse effects can be increased when Clemastine is combined with Ifenprodil.
DB00285
The risk or severity of adverse effects can be increased when Venlafaxine is combined with Ifenprodil.
DB00289
The risk or severity of adverse effects can be increased when Atomoxetine is combined with Ifenprodil.
DB00292
The risk or severity of adverse effects can be increased when Etomidate is combined with Ifenprodil.
DB00295
The risk or severity of adverse effects can be increased when Morphine is combined with Ifenprodil.
DB00306
The risk or severity of adverse effects can be increased when Talbutal is combined with Ifenprodil.
DB00312
The risk or severity of adverse effects can be increased when Pentobarbital is combined with Ifenprodil.
DB00313
The risk or severity of adverse effects can be increased when Valproic acid is combined with Ifenprodil.
DB00315
The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Ifenprodil.
DB00318
The risk or severity of adverse effects can be increased when Codeine is combined with Ifenprodil.
DB00320
The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Ifenprodil.
DB00323
The risk or severity of adverse effects can be increased when Tolcapone is combined with Ifenprodil.
DB00327
The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ifenprodil.
DB00341
The risk or severity of adverse effects can be increased when Cetirizine is combined with Ifenprodil.
DB00344
The risk or severity of adverse effects can be increased when Protriptyline is combined with Ifenprodil.
DB00347
The risk or severity of adverse effects can be increased when Trimethadione is combined with Ifenprodil.
DB00349
The risk or severity of adverse effects can be increased when Clobazam is combined with Ifenprodil.
DB00356
The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Ifenprodil.
DB00371
The risk or severity of adverse effects can be increased when Meprobamate is combined with Ifenprodil.
DB00372
The risk or severity of adverse effects can be increased when Thiethylperazine is combined with Ifenprodil.
DB00377
The risk or severity of adverse effects can be increased when Palonosetron is combined with Ifenprodil.
DB00391
The risk or severity of adverse effects can be increased when Sulpiride is combined with Ifenprodil.
DB00404
The risk or severity of adverse effects can be increased when Alprazolam is combined with Ifenprodil.
DB00405
The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ifenprodil.
DB00409
The risk or severity of adverse effects can be increased when Remoxipride is combined with Ifenprodil.
DB00416
The risk or severity of adverse effects can be increased when Metocurine iodide is combined with Ifenprodil.
DB00418
The risk or severity of adverse effects can be increased when Secobarbital is combined with Ifenprodil.
DB00423
The risk or severity of adverse effects can be increased when Methocarbamol is combined with Ifenprodil.
DB00427
The risk or severity of adverse effects can be increased when Triprolidine is combined with Ifenprodil.
DB00454
The risk or severity of adverse effects can be increased when Meperidine is combined with Ifenprodil.
DB00463
The risk or severity of adverse effects can be increased when Metharbital is combined with Ifenprodil.
DB00468
The risk or severity of adverse effects can be increased when Quinine is combined with Ifenprodil.
DB00474
The risk or severity of adverse effects can be increased when Methohexital is combined with Ifenprodil.
DB00475
The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Ifenprodil.
DB00483
The risk or severity of adverse effects can be increased when Gallamine triethiodide is combined with Ifenprodil.
DB00494
The risk or severity of adverse effects can be increased when Entacapone is combined with Ifenprodil.
DB00497
The risk or severity of adverse effects can be increased when Oxycodone is combined with Ifenprodil.
DB00508
The risk or severity of adverse effects can be increased when Triflupromazine is combined with Ifenprodil.
DB00514
The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Ifenprodil.
DB00532
The risk or severity of adverse effects can be increased when Mephenytoin is combined with Ifenprodil.
DB00546
The risk or severity of adverse effects can be increased when Adinazolam is combined with Ifenprodil.
DB00555
The risk or severity of adverse effects can be increased when Lamotrigine is combined with Ifenprodil.
DB00565
The risk or severity of adverse effects can be increased when Cisatracurium is combined with Ifenprodil.
DB00574
The risk or severity of adverse effects can be increased when Fenfluramine is combined with Ifenprodil.
DB00579
The risk or severity of adverse effects can be increased when Mazindol is combined with Ifenprodil.
DB00588
The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Ifenprodil.
DB00589
The risk or severity of adverse effects can be increased when Lisuride is combined with Ifenprodil.
DB00593
The risk or severity of adverse effects can be increased when Ethosuximide is combined with Ifenprodil.
DB00599
The risk or severity of adverse effects can be increased when Thiopental is combined with Ifenprodil.
DB00601
The risk or severity of adverse effects can be increased when Linezolid is combined with Ifenprodil.
DB00604
The risk or severity of adverse effects can be increased when Cisapride is combined with Ifenprodil.
DB00611
The risk or severity of adverse effects can be increased when Butorphanol is combined with Ifenprodil.
DB00614
The risk or severity of adverse effects can be increased when Furazolidone is combined with Ifenprodil.
DB00617
The risk or severity of adverse effects can be increased when Paramethadione is combined with Ifenprodil.
DB00625
The risk or severity of adverse effects can be increased when Efavirenz is combined with Ifenprodil.
DB00628
The risk or severity of adverse effects can be increased when Clorazepic acid is combined with Ifenprodil.
DB00633
The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Ifenprodil.
DB00645
The risk or severity of adverse effects can be increased when Dyclonine is combined with Ifenprodil.
DB00647
The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ifenprodil.
DB00652
The risk or severity of adverse effects can be increased when Pentazocine is combined with Ifenprodil.
DB00660
The risk or severity of adverse effects can be increased when Metaxalone is combined with Ifenprodil.
DB00662
The risk or severity of adverse effects can be increased when Trimethobenzamide is combined with Ifenprodil.
DB00669
The risk or severity of adverse effects can be increased when Sumatriptan is combined with Ifenprodil.
DB00680
The risk or severity of adverse effects can be increased when Moricizine is combined with Ifenprodil.
DB00683
The risk or severity of adverse effects can be increased when Midazolam is combined with Ifenprodil.
DB00690
The risk or severity of adverse effects can be increased when Flurazepam is combined with Ifenprodil.
DB00696
The risk or severity of adverse effects can be increased when Ergotamine is combined with Ifenprodil.
DB00697
The risk or severity of adverse effects can be increased when Tizanidine is combined with Ifenprodil.
DB00708
The risk or severity of adverse effects can be increased when Sufentanil is combined with Ifenprodil.
DB00714
The risk or severity of adverse effects can be increased when Apomorphine is combined with Ifenprodil.
DB00721
The risk or severity of adverse effects can be increased when Procaine is combined with Ifenprodil.
DB00726
The risk or severity of adverse effects can be increased when Trimipramine is combined with Ifenprodil.
DB00728
The risk or severity of adverse effects can be increased when Rocuronium is combined with Ifenprodil.
DB00732
The risk or severity of adverse effects can be increased when Atracurium besylate is combined with Ifenprodil.
DB00737
The risk or severity of adverse effects can be increased when Meclizine is combined with Ifenprodil.
DB00740
The risk or severity of adverse effects can be increased when Riluzole is combined with Ifenprodil.
DB00747
The risk or severity of adverse effects can be increased when Scopolamine is combined with Ifenprodil.
DB00748
The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Ifenprodil.
DB00752
The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ifenprodil.
DB00753
The risk or severity of adverse effects can be increased when Isoflurane is combined with Ifenprodil.
DB00754
The risk or severity of adverse effects can be increased when Ethotoin is combined with Ifenprodil.
DB00757
The risk or severity of adverse effects can be increased when Dolasetron is combined with Ifenprodil.
DB00771
The risk or severity of adverse effects can be increased when Clidinium is combined with Ifenprodil.
DB00776
The risk or severity of adverse effects can be increased when Oxcarbazepine is combined with Ifenprodil.
DB00780
The risk or severity of adverse effects can be increased when Phenelzine is combined with Ifenprodil.
DB00794
The risk or severity of adverse effects can be increased when Primidone is combined with Ifenprodil.
DB00801
The risk or severity of adverse effects can be increased when Halazepam is combined with Ifenprodil.
DB00802
The risk or severity of adverse effects can be increased when Alfentanil is combined with Ifenprodil.
DB00805
The risk or severity of adverse effects can be increased when Minaprine is combined with Ifenprodil.
DB00813
The risk or severity of adverse effects can be increased when Fentanyl is combined with Ifenprodil.
DB00818
The risk or severity of adverse effects can be increased when Propofol is combined with Ifenprodil.
DB00819
The risk or severity of adverse effects can be increased when Acetazolamide is combined with Ifenprodil.
DB00829
The risk or severity of adverse effects can be increased when Diazepam is combined with Ifenprodil.
DB00832
The risk or severity of adverse effects can be increased when Phensuximide is combined with Ifenprodil.
DB00835
The risk or severity of adverse effects can be increased when Brompheniramine is combined with Ifenprodil.
DB00837
The risk or severity of adverse effects can be increased when Progabide is combined with Ifenprodil.
DB00842
The risk or severity of adverse effects can be increased when Oxazepam is combined with Ifenprodil.
DB00843
The risk or severity of adverse effects can be increased when Donepezil is combined with Ifenprodil.
DB00844
The risk or severity of adverse effects can be increased when Nalbuphine is combined with Ifenprodil.
DB00849
The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Ifenprodil.
DB00854
The risk or severity of adverse effects can be increased when Levorphanol is combined with Ifenprodil.
DB00866
The risk or severity of adverse effects can be increased when Alprenolol is combined with Ifenprodil.
DB00889
The risk or severity of adverse effects can be increased when Granisetron is combined with Ifenprodil.
DB00897
The risk or severity of adverse effects can be increased when Triazolam is combined with Ifenprodil.
DB00899
The risk or severity of adverse effects can be increased when Remifentanil is combined with Ifenprodil.
DB00904
The risk or severity of adverse effects can be increased when Ondansetron is combined with Ifenprodil.
DB00906
The risk or severity of adverse effects can be increased when Tiagabine is combined with Ifenprodil.
DB00909
The risk or severity of adverse effects can be increased when Zonisamide is combined with Ifenprodil.
DB00918
The risk or severity of adverse effects can be increased when Almotriptan is combined with Ifenprodil.
DB00941
The risk or severity of adverse effects can be increased when Hexafluronium is combined with Ifenprodil.
DB00949
The risk or severity of adverse effects can be increased when Felbamate is combined with Ifenprodil.
DB00952
The risk or severity of adverse effects can be increased when Naratriptan is combined with Ifenprodil.
DB00953
The risk or severity of adverse effects can be increased when Rizatriptan is combined with Ifenprodil.
DB00960
The risk or severity of adverse effects can be increased when Pindolol is combined with Ifenprodil.
DB00962
The risk or severity of adverse effects can be increased when Zaleplon is combined with Ifenprodil.
DB00967
The risk or severity of adverse effects can be increased when Desloratadine is combined with Ifenprodil.
DB00969
The risk or severity of adverse effects can be increased when Alosetron is combined with Ifenprodil.
DB00980
The risk or severity of adverse effects can be increased when Ramelteon is combined with Ifenprodil.
DB00985
The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Ifenprodil.
DB00996
The risk or severity of adverse effects can be increased when Gabapentin is combined with Ifenprodil.
DB00998
The risk or severity of adverse effects can be increased when Frovatriptan is combined with Ifenprodil.
DB01018
The risk or severity of adverse effects can be increased when Guanfacine is combined with Ifenprodil.
DB01028
The risk or severity of adverse effects can be increased when Methoxyflurane is combined with Ifenprodil.
DB01037
The risk or severity of adverse effects can be increased when Selegiline is combined with Ifenprodil.
DB01049
The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Ifenprodil.
DB01063
The risk or severity of adverse effects can be increased when Acetophenazine is combined with Ifenprodil.
DB01065
The risk or severity of adverse effects can be increased when Melatonin is combined with Ifenprodil.
DB01068
The risk or severity of adverse effects can be increased when Clonazepam is combined with Ifenprodil.
DB01069
The risk or severity of adverse effects can be increased when Promethazine is combined with Ifenprodil.
DB01075
The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ifenprodil.
DB01080
The risk or severity of adverse effects can be increased when Vigabatrin is combined with Ifenprodil.
DB01081
The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ifenprodil.
DB01107
The risk or severity of adverse effects can be increased when Methyprylon is combined with Ifenprodil.
DB01114
The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Ifenprodil.
DB01121
The risk or severity of adverse effects can be increased when Phenacemide is combined with Ifenprodil.
DB01135
The risk or severity of adverse effects can be increased when Doxacurium is combined with Ifenprodil.
DB01154
The risk or severity of adverse effects can be increased when Thiamylal is combined with Ifenprodil.
DB01159
The risk or severity of adverse effects can be increased when Halothane is combined with Ifenprodil.
DB01168
The risk or severity of adverse effects can be increased when Procarbazine is combined with Ifenprodil.
DB01171
The risk or severity of adverse effects can be increased when Moclobemide is combined with Ifenprodil.
DB01174
The risk or severity of adverse effects can be increased when Phenobarbital is combined with Ifenprodil.
DB01176
The risk or severity of adverse effects can be increased when Cyclizine is combined with Ifenprodil.
DB01178
The risk or severity of adverse effects can be increased when Chlormezanone is combined with Ifenprodil.
DB01186
The risk or severity of adverse effects can be increased when Pergolide is combined with Ifenprodil.
DB01189
The risk or severity of adverse effects can be increased when Desflurane is combined with Ifenprodil.
DB01192
The risk or severity of adverse effects can be increased when Oxymorphone is combined with Ifenprodil.
DB01199
The risk or severity of adverse effects can be increased when Tubocurarine is combined with Ifenprodil.
DB01200
The risk or severity of adverse effects can be increased when Bromocriptine is combined with Ifenprodil.
DB01202
The risk or severity of adverse effects can be increased when Levetiracetam is combined with Ifenprodil.
DB01209
The risk or severity of adverse effects can be increased when Dezocine is combined with Ifenprodil.
DB01215
The risk or severity of adverse effects can be increased when Estazolam is combined with Ifenprodil.
DB01219
The risk or severity of adverse effects can be increased when Dantrolene is combined with Ifenprodil.
DB01221
The risk or severity of adverse effects can be increased when Ketamine is combined with Ifenprodil.
DB01226
The risk or severity of adverse effects can be increased when Mivacurium is combined with Ifenprodil.
DB01227
The risk or severity of adverse effects can be increased when Levacetylmethadol is combined with Ifenprodil.
DB01235
The risk or severity of adverse effects can be increased when Levodopa is combined with Ifenprodil.
DB01236
The risk or severity of adverse effects can be increased when Sevoflurane is combined with Ifenprodil.
DB01242
The risk or severity of adverse effects can be increased when Clomipramine is combined with Ifenprodil.
DB01245
The risk or severity of adverse effects can be increased when Decamethonium is combined with Ifenprodil.
DB01246
The risk or severity of adverse effects can be increased when Alimemazine is combined with Ifenprodil.
DB01247
The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Ifenprodil.
DB01253
The risk or severity of adverse effects can be increased when Ergometrine is combined with Ifenprodil.
DB01320
The risk or severity of adverse effects can be increased when Fosphenytoin is combined with Ifenprodil.
DB01323
The risk or severity of adverse effects can be increased when St. John's Wort is combined with Ifenprodil.
DB01336
The risk or severity of adverse effects can be increased when Metocurine is combined with Ifenprodil.
DB01337
The risk or severity of adverse effects can be increased when Pancuronium is combined with Ifenprodil.
DB01338
The risk or severity of adverse effects can be increased when Pipecuronium is combined with Ifenprodil.
DB01339
The risk or severity of adverse effects can be increased when Vecuronium is combined with Ifenprodil.
DB01351
The risk or severity of adverse effects can be increased when Amobarbital is combined with Ifenprodil.
DB01352
The risk or severity of adverse effects can be increased when Aprobarbital is combined with Ifenprodil.
DB01353
The risk or severity of adverse effects can be increased when Butobarbital is combined with Ifenprodil.
DB01354
The risk or severity of adverse effects can be increased when Heptabarbital is combined with Ifenprodil.
DB01355
The risk or severity of adverse effects can be increased when Hexobarbital is combined with Ifenprodil.
DB01356
The risk or severity of adverse effects can be increased when Lithium cation is combined with Ifenprodil.
DB01359
The risk or severity of adverse effects can be increased when Penbutolol is combined with Ifenprodil.
DB01367
The risk or severity of adverse effects can be increased when Rasagiline is combined with Ifenprodil.
DB01392
The risk or severity of adverse effects can be increased when Yohimbine is combined with Ifenprodil.
DB01433
The risk or severity of adverse effects can be increased when Methadyl acetate is combined with Ifenprodil.
DB01437
The risk or severity of adverse effects can be increased when Glutethimide is combined with Ifenprodil.
DB01440
The risk or severity of adverse effects can be increased when gamma-Hydroxybutyric acid is combined with Ifenprodil.
DB01445
The risk or severity of adverse effects can be increased when Bufotenine is combined with Ifenprodil.
DB01450
The risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Ifenprodil.
DB01452
The risk or severity of adverse effects can be increased when Diamorphine is combined with Ifenprodil.
DB01463
The risk or severity of adverse effects can be increased when Fencamfamin is combined with Ifenprodil.
DB01466
The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Ifenprodil.
DB01472
The risk or severity of adverse effects can be increased when 4-Methoxyamphetamine is combined with Ifenprodil.
DB01483
The risk or severity of adverse effects can be increased when Barbital is combined with Ifenprodil.
DB01488
The risk or severity of adverse effects can be increased when Dimethyltryptamine is combined with Ifenprodil.
DB01489
The risk or severity of adverse effects can be increased when Camazepam is combined with Ifenprodil.
DB01495
The risk or severity of adverse effects can be increased when Dichloralphenazone is combined with Ifenprodil.
DB01497
The risk or severity of adverse effects can be increased when Etorphine is combined with Ifenprodil.
DB01501
The risk or severity of adverse effects can be increased when Difenoxin is combined with Ifenprodil.
DB01511
The risk or severity of adverse effects can be increased when Delorazepam is combined with Ifenprodil.
DB01529
The risk or severity of adverse effects can be increased when Dextromoramide is combined with Ifenprodil.
DB01531
The risk or severity of adverse effects can be increased when Desomorphine is combined with Ifenprodil.
DB01534
The risk or severity of adverse effects can be increased when Chlorhexadol is combined with Ifenprodil.
DB01535
The risk or severity of adverse effects can be increased when Carfentanil is combined with Ifenprodil.
DB01544
The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Ifenprodil.
DB01545
The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Ifenprodil.
DB01547
The risk or severity of adverse effects can be increased when Drotebanol is combined with Ifenprodil.
DB01551
The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ifenprodil.
DB01553
The risk or severity of adverse effects can be increased when Cloxazolam is combined with Ifenprodil.
DB01555
The risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Ifenprodil.
DB01558
The risk or severity of adverse effects can be increased when Bromazepam is combined with Ifenprodil.
DB01559
The risk or severity of adverse effects can be increased when Clotiazepam is combined with Ifenprodil.
DB01560
The risk or severity of adverse effects can be increased when Cathinone is combined with Ifenprodil.
DB01563
The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Ifenprodil.
DB01565
The risk or severity of adverse effects can be increased when Dihydromorphine is combined with Ifenprodil.
DB01567
The risk or severity of adverse effects can be increased when Fludiazepam is combined with Ifenprodil.
DB01580
The risk or severity of adverse effects can be increased when Oxprenolol is combined with Ifenprodil.
DB01587
The risk or severity of adverse effects can be increased when Ketazolam is combined with Ifenprodil.
DB01588
The risk or severity of adverse effects can be increased when Prazepam is combined with Ifenprodil.
DB01589
The risk or severity of adverse effects can be increased when Quazepam is combined with Ifenprodil.
DB01594
The risk or severity of adverse effects can be increased when Cinolazepam is combined with Ifenprodil.
DB01595
The risk or severity of adverse effects can be increased when Nitrazepam is combined with Ifenprodil.
DB01614
The risk or severity of adverse effects can be increased when Acepromazine is combined with Ifenprodil.
DB01615
The risk or severity of adverse effects can be increased when Aceprometazine is combined with Ifenprodil.
DB01616
The risk or severity of adverse effects can be increased when Alverine is combined with Ifenprodil.
DB01621
The risk or severity of adverse effects can be increased when Pipotiazine is combined with Ifenprodil.
DB01626
The risk or severity of adverse effects can be increased when Pargyline is combined with Ifenprodil.
DB01954
The risk or severity of adverse effects can be increased when Rolipram is combined with Ifenprodil.
DB02207
The risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Ifenprodil.
DB02234
The risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Ifenprodil.
DB02852
The risk or severity of adverse effects can be increased when Domoic Acid is combined with Ifenprodil.
DB02959
The risk or severity of adverse effects can be increased when Oxitriptan is combined with Ifenprodil.
DB03575
The risk or severity of adverse effects can be increased when Phencyclidine is combined with Ifenprodil.
DB04017
The risk or severity of adverse effects can be increased when Clorgiline is combined with Ifenprodil.
DB04165
The risk or severity of adverse effects can be increased when Valpromide is combined with Ifenprodil.
DB04325
The risk or severity of adverse effects can be increased when Phenethylamine is combined with Ifenprodil.
DB04599
The risk or severity of adverse effects can be increased when Aniracetam is combined with Ifenprodil.
DB04818
The risk or severity of adverse effects can be increased when Iproniazid is combined with Ifenprodil.
DB04819
The risk or severity of adverse effects can be increased when Methapyrilene is combined with Ifenprodil.
DB04820
The risk or severity of adverse effects can be increased when Nialamide is combined with Ifenprodil.
DB04821
The risk or severity of adverse effects can be increased when Nomifensine is combined with Ifenprodil.
DB04827
The risk or severity of adverse effects can be increased when Urethane is combined with Ifenprodil.
DB04829
The risk or severity of adverse effects can be increased when Lysergic acid diethylamide is combined with Ifenprodil.
DB04833
The risk or severity of adverse effects can be increased when Methaqualone is combined with Ifenprodil.
DB04834
The risk or severity of adverse effects can be increased when Rapacuronium is combined with Ifenprodil.
DB04836
The risk or severity of adverse effects can be increased when Amineptine is combined with Ifenprodil.
DB04841
The risk or severity of adverse effects can be increased when Flunarizine is combined with Ifenprodil.
DB04842
The risk or severity of adverse effects can be increased when Fluspirilene is combined with Ifenprodil.
DB04871
The risk or severity of adverse effects can be increased when Lorcaserin is combined with Ifenprodil.
DB04872
The risk or severity of adverse effects can be increased when Osanetant is combined with Ifenprodil.
DB04885
The risk or severity of adverse effects can be increased when Cilansetron is combined with Ifenprodil.
DB04903
The risk or severity of adverse effects can be increased when Pagoclone is combined with Ifenprodil.
DB04908
The risk or severity of adverse effects can be increased when Flibanserin is combined with Ifenprodil.
DB04917
The risk or severity of adverse effects can be increased when Renzapride is combined with Ifenprodil.
DB04953
The risk or severity of adverse effects can be increased when Ezogabine is combined with Ifenprodil.
DB05227
The risk or severity of adverse effects can be increased when APD791 is combined with Ifenprodil.
DB05232
The risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Ifenprodil.
DB05246
The risk or severity of adverse effects can be increased when Methsuximide is combined with Ifenprodil.
DB05541
The risk or severity of adverse effects can be increased when Brivaracetam is combined with Ifenprodil.
DB05542
The risk or severity of adverse effects can be increased when Naronapride is combined with Ifenprodil.
DB05562
The risk or severity of adverse effects can be increased when Naluzotan is combined with Ifenprodil.
DB05607
The risk or severity of adverse effects can be increased when PRX-08066 is combined with Ifenprodil.
DB05687
The risk or severity of adverse effects can be increased when BL-1020 is combined with Ifenprodil.
DB05710
The risk or severity of adverse effects can be increased when Gantacurium is combined with Ifenprodil.
DB06109
The risk or severity of adverse effects can be increased when YKP-1358 is combined with Ifenprodil.
DB06218
The risk or severity of adverse effects can be increased when Lacosamide is combined with Ifenprodil.
DB06264
The risk or severity of adverse effects can be increased when Tolperisone is combined with Ifenprodil.
DB06282
The risk or severity of adverse effects can be increased when Levocetirizine is combined with Ifenprodil.
DB06446
The risk or severity of adverse effects can be increased when Dotarizine is combined with Ifenprodil.
DB06458
The risk or severity of adverse effects can be increased when Remacemide is combined with Ifenprodil.
DB06470
The risk or severity of adverse effects can be increased when Clomethiazole is combined with Ifenprodil.
DB06512
The risk or severity of adverse effects can be increased when Deramciclane is combined with Ifenprodil.
DB06527
The risk or severity of adverse effects can be increased when Tramiprosate is combined with Ifenprodil.
DB06529
The risk or severity of adverse effects can be increased when Ocinaplon is combined with Ifenprodil.
DB06554
The risk or severity of adverse effects can be increased when Gaboxadol is combined with Ifenprodil.
DB06579
The risk or severity of adverse effects can be increased when Adipiplon is combined with Ifenprodil.
DB06582
The risk or severity of adverse effects can be increased when Dextofisopam is combined with Ifenprodil.
DB06594
The risk or severity of adverse effects can be increased when Agomelatine is combined with Ifenprodil.
DB06654
The risk or severity of adverse effects can be increased when Safinamide is combined with Ifenprodil.
DB06660
The risk or severity of adverse effects can be increased when Saredutant is combined with Ifenprodil.
DB06678
The risk or severity of adverse effects can be increased when Esmirtazapine is combined with Ifenprodil.
DB06684
The risk or severity of adverse effects can be increased when Vilazodone is combined with Ifenprodil.
DB06690
The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Ifenprodil.
DB06691
The risk or severity of adverse effects can be increased when Mepyramine is combined with Ifenprodil.
DB06716
The risk or severity of adverse effects can be increased when Fospropofol is combined with Ifenprodil.
DB06738
The risk or severity of adverse effects can be increased when Ketobemidone is combined with Ifenprodil.
DB06753
The risk or severity of adverse effects can be increased when Triclofos is combined with Ifenprodil.
DB06770
The risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Ifenprodil.
DB06797
The risk or severity of adverse effects can be increased when Mebutamate is combined with Ifenprodil.
DB08059
The risk or severity of adverse effects can be increased when Wortmannin is combined with Ifenprodil.
DB08329
The risk or severity of adverse effects can be increased when Sulthiame is combined with Ifenprodil.
DB08550
The risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Ifenprodil.
DB08810
The risk or severity of adverse effects can be increased when Cinitapride is combined with Ifenprodil.
DB08811
The risk or severity of adverse effects can be increased when Tofisopam is combined with Ifenprodil.
DB08839
The risk or severity of adverse effects can be increased when Serotonin is combined with Ifenprodil.
DB08861
The risk or severity of adverse effects can be increased when DPDPE is combined with Ifenprodil.
DB08872
The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Ifenprodil.
DB08892
The risk or severity of adverse effects can be increased when Arbaclofen Placarbil is combined with Ifenprodil.
DB08910
The risk or severity of adverse effects can be increased when Pomalidomide is combined with Ifenprodil.
DB08927
The risk or severity of adverse effects can be increased when Amperozide is combined with Ifenprodil.
DB08960
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Hexamethonium.
DB08986
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Etifoxine.
DB08992
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Eperisone.
DB08996
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Dimetacrine.
DB09000
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Cyamemazine.
DB09001
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Barbexaclone.
DB09011
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Beclamide.
DB09014
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Captodiame.
DB09016
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Butriptyline.
DB09017
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Brotizolam.
DB09021
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Benzoctamine.
DB09023
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Benactyzine.
DB09068
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Vortioxetine.
DB09071
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Tasimelteon.
DB09118
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Stiripentol.
DB09119
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Eslicarbazepine acetate.
DB09166
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Etizolam.
DB09174
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Lofentanil.
DB09184
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Edivoxetine.
DB09185
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Viloxazine.
DB09186
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Nisoxetine.
DB09187
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Lortalamine.
DB09190
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Talopram.
DB09194
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Etoperidone.
DB09241
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Methylene blue.
DB09243
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Hydracarbazine.
DB09244
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Pirlindole.
DB09245
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Toloxatone.
DB09246
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Benmoxin.
DB09247
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Iproclozide.
DB09248
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Mebanazine.
DB09249
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Octamoxin.
DB09250
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Pheniprazine.
DB09251
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Phenoxypropazine.
DB09252
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Pivhydrazine.
DB09253
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Safrazine.
DB09254
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Caroxazone.
DB09286
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Pipamperone.
DB09289
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Tianeptine.
DB09290
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Ramosetron.
DB09307
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Oxaprotiline.
DB11130
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Opium.
DB11156
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Pyrantel.
DB11371
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Alfaxalone.
DB11400
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Doramectin.
DB11428
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Medetomidine.
DB11477
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Xylazine.
DB11540
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Propiopromazine.
DB11543
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Romifidine.
DB11549
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Tiletamine.
DB11552
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Tricaine.
DB11555
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Zolazepam.
DB11556
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Detomidine.
DB11582
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Thiocolchicoside.
DB11609
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Normethadone.
DB11664
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Psilocybin.
DB11675
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Mosapride.
DB11686
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Iferanserin.
DB11699
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Tropisetron.
DB11755
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Tetrahydrocannabivarin.
DB11859
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Brexanolone.
DB11868
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Etiracetam.
DB11889
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Lanicemine.
DB11957
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Idalopirdine.
DB12071
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Vabicaserin.
DB12093
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Tetrahydropalmatine.
DB12105
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Imagabalin.
DB12110
The risk or severity of adverse effects can be increased when Ifenprodil is combined with m-Chlorophenylpiperazine.
DB12111
The risk or severity of adverse effects can be increased when Ifenprodil is combined with MK-212.
DB12131
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Vinpocetine.
DB12163
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Sarpogrelate.
DB12177
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Eplivanserin.
DB12184
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Gepirone.
DB12229
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Cerlapirdine.
DB12273
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Ecopipam.
DB12308
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Eltanolone.
DB12327
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Salvinorin A.
DB12338
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Carisbamate.
DB12361
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Piclozotan.
DB12395
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Esreboxetine.
DB12401
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Bromperidol.
DB12427
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Orvepitant.
DB12465
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Ketanserin.
DB12492
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Piritramide.
DB12518
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Raclopride.
DB12537
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Benzodiazepine.
DB12576
The risk or severity of adverse effects can be increased when Ifenprodil is combined with AZD-3043.
DB12590
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Indiplon.
DB12661
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Urapidil.
DB12710
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Perazine.
DB12725
The risk or severity of adverse effects can be increased when Ifenprodil is combined with TD-8954.
DB12833
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Tandospirone.
DB12867
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Benperidol.
DB12883
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Eltoprazine.
DB12930
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Opipramol.
DB12951
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Pivagabine.
DB12958
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Prothipendyl.
DB12989
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Neosaxitoxin.
DB13014
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Hypericin.
DB13025
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Tiapride.
DB13082
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Nefiracetam.
DB13099
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Valnoctamide.
DB13114
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Amitriptylinoxide.
DB13160
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Alphaprodine.
DB13213
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Butaperazine.
DB13219
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Medifoxamine.
DB13221
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Apronalide.
DB13225
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Dibenzepin.
DB13234
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Propanidid.
DB13246
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Quinupramine.
DB13253
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Proxibarbal.
DB13256
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Clothiapine.
DB13273
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Sultopride.
DB13295
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Atracurium.
DB13303
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Febarbamate.
DB13323
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Trichloroethylene.
DB13324
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Tetrazepam.
DB13331
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Pyrithyldione.
DB13335
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Pinazepam.
DB13352
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Deanol.
DB13354
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Phenprobamate.
DB13357
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Styramate.
DB13362
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Pheneturide.
DB13370
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Bromisoval.
DB13377
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Vinbarbital.
DB13382
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Chlorproethazine.
DB13384
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Melitracen.
DB13396
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Neocitrullamon.
DB13402
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Acetylglycinamide chloral hydrate.
DB13403
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Oxypertine.
DB13411
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Lofepramine.
DB13414
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Fenyramidol.
DB13420
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Thiazinam.
DB13437
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Medazepam.
DB13454
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Nicomorphine.
DB13455
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Phenibut.
DB13457
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Oxaflozane.
DB13478
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Meptazinol.
DB13496
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Iprindole.
DB13505
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Emepronium.
DB13520
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Metergoline.
DB13522
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Mebicar.
DB13523
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Veralipride.
DB13534
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Gedocarnil.
DB13541
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Iprazochrome.
DB13550
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Bifemelane.
DB13552
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Trifluperidol.
DB13554
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Moperone.
DB13557
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Thiopropazate.
DB13572
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Emylcamate.
DB13577
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Allobarbital.
DB13584
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Gallamine.
DB13588
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Naftidrofuryl.
DB13598
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Diethyl ether.
DB13601
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Oxiracetam.
DB13605
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Phenoperidine.
DB13606
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Phenazocine.
DB13623
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Fabomotizole.
DB13642
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Pridinol.
DB13643
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Loprazolam.
DB13648
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Alcuronium.
DB13662
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Hexapropymate.
DB13665
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Fluanisone.
DB13676
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Mosapramine.
DB13687
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Niaprazine.
DB13690
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Vinyl ether.
DB13733
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Methylpentynol.
DB13737
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Cyclobarbital.
DB13745
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Fazadinium bromide.
DB13754
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Mephenoxalone.
DB13770
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Vinylbital.
DB13782
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Imipramine oxide.
DB13784
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Dixyrazine.
DB13787
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Tilidine.
DB13791
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Penfluridol.
DB13799
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Ethadione.
DB13805
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Reposal.
DB13817
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Carbromal.
DB13837
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Doxefazepam.
DB13841
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Clopenthixol.
DB13872
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Lormetazepam.
DB13875
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Harmaline.
DB13876
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Brofaromine.
DB13948
The risk or severity of adverse effects can be increased when Ifenprodil is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine.
DB13984
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Cyclopropane.
DB13993
The risk or severity of adverse effects can be increased when Ifenprodil is combined with MRK-409.
DB14010
The risk or severity of adverse effects can be increased when Ifenprodil is combined with 5-methoxy-N,N-dimethyltryptamine.
DB14028
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Nordazepam.
DB14050
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Cannabidivarin.
DB14185
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Aripiprazole lauroxil.
DB14509
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Lithium carbonate.
DB14575
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Eslicarbazepine.
DB14651
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Perphenazine enanthate.
DB14672
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Oxazepam acetate.
DB14715
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Cinazepam.
DB14718
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Pyrazolam.
DB14719
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Bentazepam.
DB15203
The risk or severity of adverse effects can be increased when Ifenprodil is combined with JNJ-26489112.
DB15360
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Carfentanil, C-11.
DB11951
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Lemborexant.
DB00751
The risk or severity of adverse effects can be increased when Epinastine is combined with Ifenprodil.
DB00230
The therapeutic efficacy of Ifenprodil can be increased when used in combination with Pregabalin.
DB00201
Ifenprodil may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.
DB00277
Ifenprodil may increase the excretion rate of Theophylline which could result in a lower serum level and potentially a reduction in efficacy.
DB00651
Ifenprodil may increase the excretion rate of Dyphylline which could result in a lower serum level and potentially a reduction in efficacy.
DB00806
Ifenprodil may increase the excretion rate of Pentoxifylline which could result in a lower serum level and potentially a reduction in efficacy.
DB01033
Ifenprodil may increase the excretion rate of Mercaptopurine which could result in a lower serum level and potentially a reduction in efficacy.
DB01223
Ifenprodil may increase the excretion rate of Aminophylline which could result in a lower serum level and potentially a reduction in efficacy.
DB01303
Ifenprodil may increase the excretion rate of Oxtriphylline which could result in a lower serum level and potentially a reduction in efficacy.
DB01412
Ifenprodil may increase the excretion rate of Theobromine which could result in a lower serum level and potentially a reduction in efficacy.
DB01482
Ifenprodil may increase the excretion rate of Fenethylline which could result in a lower serum level and potentially a reduction in efficacy.
DB01667
Ifenprodil may increase the excretion rate of 8-azaguanine which could result in a lower serum level and potentially a reduction in efficacy.
DB01978
Ifenprodil may increase the excretion rate of 7,9-Dimethylguanine which could result in a lower serum level and potentially a reduction in efficacy.
DB02134
Ifenprodil may increase the excretion rate of Xanthine which could result in a lower serum level and potentially a reduction in efficacy.
DB02245
Ifenprodil may increase the excretion rate of 7-Deazaguanine which could result in a lower serum level and potentially a reduction in efficacy.
DB02377
Ifenprodil may increase the excretion rate of Guanine which could result in a lower serum level and potentially a reduction in efficacy.
DB02489
Ifenprodil may increase the excretion rate of 9-Methylguanine which could result in a lower serum level and potentially a reduction in efficacy.
DB02568
Ifenprodil may increase the excretion rate of Peldesine which could result in a lower serum level and potentially a reduction in efficacy.
DB04076
Ifenprodil may increase the excretion rate of Hypoxanthine which could result in a lower serum level and potentially a reduction in efficacy.
DB04356
Ifenprodil may increase the excretion rate of 9-Deazaguanine which could result in a lower serum level and potentially a reduction in efficacy.
DB06479
Ifenprodil may increase the excretion rate of Propentofylline which could result in a lower serum level and potentially a reduction in efficacy.
DB06575
Ifenprodil may increase the excretion rate of Valomaciclovir which could result in a lower serum level and potentially a reduction in efficacy.
DB07954
Ifenprodil may increase the excretion rate of 3-isobutyl-1-methyl-7H-xanthine which could result in a lower serum level and potentially a reduction in efficacy.
DB08844
Ifenprodil may increase the excretion rate of Uric acid which could result in a lower serum level and potentially a reduction in efficacy.
DB09273
Ifenprodil may increase the excretion rate of Doxofylline which could result in a lower serum level and potentially a reduction in efficacy.
DB11919
Ifenprodil may increase the excretion rate of 6-O-benzylguanine which could result in a lower serum level and potentially a reduction in efficacy.
DB12406
Ifenprodil may increase the excretion rate of Lisofylline which could result in a lower serum level and potentially a reduction in efficacy.
DB12531
Ifenprodil may increase the excretion rate of Lobucavir which could result in a lower serum level and potentially a reduction in efficacy.
DB12926
Ifenprodil may increase the excretion rate of Cafedrine which could result in a lower serum level and potentially a reduction in efficacy.
DB12927
Ifenprodil may increase the excretion rate of Theodrenaline which could result in a lower serum level and potentially a reduction in efficacy.
DB13203
Ifenprodil may increase the excretion rate of Bamifylline which could result in a lower serum level and potentially a reduction in efficacy.
DB13449
Ifenprodil may increase the excretion rate of Proxyphylline which could result in a lower serum level and potentially a reduction in efficacy.
DB13573
Ifenprodil may increase the excretion rate of Acefylline which could result in a lower serum level and potentially a reduction in efficacy.
DB13592
Ifenprodil may increase the excretion rate of Etamiphylline which could result in a lower serum level and potentially a reduction in efficacy.
DB13634
Ifenprodil may increase the excretion rate of Pentifylline which could result in a lower serum level and potentially a reduction in efficacy.
DB13812
Ifenprodil may increase the excretion rate of Bufylline which could result in a lower serum level and potentially a reduction in efficacy.
DB14018
Ifenprodil may increase the excretion rate of Bromotheophylline which could result in a lower serum level and potentially a reduction in efficacy.
DB14029
Ifenprodil may increase the excretion rate of Furafylline which could result in a lower serum level and potentially a reduction in efficacy.
DB14132
Ifenprodil may increase the excretion rate of 8-chlorotheophylline which could result in a lower serum level and potentially a reduction in efficacy.
DB15122
Ifenprodil may increase the excretion rate of PCS-499 which could result in a lower serum level and potentially a reduction in efficacy.
DB13967
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Patent Blue.
DB04948
The therapeutic efficacy of Ifenprodil can be increased when used in combination with Lofexidine.
DB01156
The risk or severity of adverse effects can be increased when Bupropion is combined with Ifenprodil.
DB05077
The risk or severity of adverse effects can be increased when SLV319 is combined with Ifenprodil.
DB06155
The risk or severity of adverse effects can be increased when Rimonabant is combined with Ifenprodil.
DB06624
The risk or severity of adverse effects can be increased when Taranabant is combined with Ifenprodil.
DB09061
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Ifenprodil.
DB11903
The risk or severity of adverse effects can be increased when GW842166 is combined with Ifenprodil.
DB12193
The risk or severity of adverse effects can be increased when Ajulemic acid is combined with Ifenprodil.
DB12649
The risk or severity of adverse effects can be increased when Ibipinabant is combined with Ifenprodil.
DB13070
The risk or severity of adverse effects can be increased when Surinabant is combined with Ifenprodil.
DB13950
The risk or severity of adverse effects can be increased when WIN 55212-2 is combined with Ifenprodil.
DB14011
The risk or severity of adverse effects can be increased when Nabiximols is combined with Ifenprodil.
DB14043
The risk or severity of adverse effects can be increased when Palmidrol is combined with Ifenprodil.
DB14737
The risk or severity of adverse effects can be increased when Cannabinol is combined with Ifenprodil.
DB00091
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Cyclosporine.
DB00281
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Lidocaine.
DB00291
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Chlorambucil.
DB00297
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Bupivacaine.
DB00397
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Phenylpropanolamine.
DB00456
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Cefalotin.
DB00493
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Cefotaxime.
DB00608
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Chloroquine.
DB00681
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Amphotericin B.
DB00719
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Azatadine.
DB00779
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Nalidixic acid.
DB00822
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Disulfiram.
DB00902
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Methdilazine.
DB00916
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Metronidazole.
DB00951
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Isoniazid.
DB01004
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Ganciclovir.
DB01061
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Azlocillin.
DB01218
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Halofantrine.
DB01598
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Imipenem.
DB01610
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Valganciclovir.
DB02136
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Cephalosporin analog.
DB03313
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Cephalosporin C.
DB03938
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Deacetoxycephalosporin C.
DB06793
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Levopropoxyphene.
DB09449
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Sodium phosphate, monobasic.
DB09555
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Dexchlorpheniramine maleate.
DB11199
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Sage oil.
DB11238
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Borage oil.
DB11358
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Evening primrose oil.
DB11447
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Phenothiazine.
DB13679
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Dexchlorpheniramine.
DB13854
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Gamolenic acid.
DB14071
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Desmethylsertraline.
DB01362
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Iohexol.
DB14256
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Centella asiatica.
DB01364
Ephedrine may decrease the hypertensive activities of Ifenprodil.
DB00368
Ifenprodil may decrease the hypertensive activities of Norepinephrine.
DB00668
Ifenprodil may decrease the hypertensive activities of Epinephrine.
DB06262
Ifenprodil may decrease the hypertensive activities of Droxidopa.
DB06707
Ifenprodil may decrease the hypertensive activities of Levonordefrin.
DB06814
Ifenprodil may decrease the hypertensive activities of Protokylol.
DB11124
Ifenprodil may decrease the hypertensive activities of Racepinephrine.
DB13917
Ifenprodil may decrease the hypertensive activities of Deoxyepinephrine.
DB14752
The therapeutic efficacy of Racephedrine can be decreased when used in combination with Ifenprodil.
DB01537
The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Ifenprodil.
DB14547
The therapeutic efficacy of Chloride ion can be decreased when used in combination with Ifenprodil.
DB00182
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Amphetamine.
DB00191
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Phentermine.
DB00852
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Pseudoephedrine.
DB00865
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Benzphetamine.
DB00937
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Diethylpropion.
DB01255
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Lisdexamfetamine.
DB01365
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Mephentermine.
DB01442
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with MMDA.
DB01454
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Midomafetamine.
DB01467
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with 2,5-Dimethoxy-4-ethylamphetamine.
DB01484
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with 4-Bromo-2,5-dimethoxyamphetamine.
DB01509
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Tenamfetamine.
DB01556
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Chlorphentermine.
DB01566
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Methylenedioxyethamphetamine.
DB01576
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Dextroamphetamine.
DB01577
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Metamfetamine.
DB09480
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Iofetamine I-123.
DB12080
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Ritobegron.
DB13108
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Mephedrone.
DB13624
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Methoxyphenamine.
DB13703
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Gepefrine.
DB13940
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with 2,5-Dimethoxy-4-ethylthioamphetamine.
DB11823
The risk or severity of hypertension can be increased when Esketamine is combined with Ifenprodil.
DB00395
The risk or severity of adverse effects can be increased when Carisoprodol is combined with Ifenprodil.
DB14754
The risk or severity of hypertension can be increased when Solriamfetol is combined with Ifenprodil.
DB13946
Testosterone undecanoate may increase the hypertensive activities of Ifenprodil.
DB00402
The risk or severity of CNS depression can be increased when Ifenprodil is combined with Eszopiclone.
DB00564
Carbamazepine may increase the Change in thyroid function activities of Ifenprodil.
DB00575
The risk or severity of sedation can be increased when Clonidine is combined with Ifenprodil.
DB00255
The metabolism of Diethylstilbestrol can be increased when combined with Ifenprodil.
DB00294
The metabolism of Etonogestrel can be increased when combined with Ifenprodil.
DB00304
The metabolism of Desogestrel can be increased when combined with Ifenprodil.
DB00351
The metabolism of Megestrol acetate can be increased when combined with Ifenprodil.
DB00367
The metabolism of Levonorgestrel can be increased when combined with Ifenprodil.
DB00396
The metabolism of Progesterone can be increased when combined with Ifenprodil.
DB00603
The metabolism of Medroxyprogesterone acetate can be increased when combined with Ifenprodil.
DB00717
The metabolism of Norethisterone can be increased when combined with Ifenprodil.
DB00783
The metabolism of Estradiol can be increased when combined with Ifenprodil.
DB00823
The metabolism of Ethynodiol diacetate can be increased when combined with Ifenprodil.
DB00834
The metabolism of Mifepristone can be increased when combined with Ifenprodil.
DB00957
The metabolism of Norgestimate can be increased when combined with Ifenprodil.
DB00977
The metabolism of Ethinylestradiol can be increased when combined with Ifenprodil.
DB01357
The metabolism of Mestranol can be increased when combined with Ifenprodil.
DB01395
The metabolism of Drospirenone can be increased when combined with Ifenprodil.
DB04066
The metabolism of p-Coumaric acid can be increased when combined with Ifenprodil.
DB04574
The metabolism of Estrone sulfate can be increased when combined with Ifenprodil.
DB04682
The metabolism of Octylphenoxy polyethoxyethanol can be increased when combined with Ifenprodil.
DB04839
The metabolism of Cyproterone acetate can be increased when combined with Ifenprodil.
DB05830
The metabolism of Trestolone can be increased when combined with Ifenprodil.
DB06266
The metabolism of Lonidamine can be increased when combined with Ifenprodil.
DB06713
The metabolism of Norelgestromin can be increased when combined with Ifenprodil.
DB06730
The metabolism of Gestodene can be increased when combined with Ifenprodil.
DB06789
The metabolism of Hydroxyprogesterone caproate can be increased when combined with Ifenprodil.
DB06804
The metabolism of Nonoxynol-9 can be increased when combined with Ifenprodil.
DB08867
The metabolism of Ulipristal can be increased when combined with Ifenprodil.
DB09123
The metabolism of Dienogest can be increased when combined with Ifenprodil.
DB09371
The metabolism of Norethynodrel can be increased when combined with Ifenprodil.
DB09389
The metabolism of Norgestrel can be increased when combined with Ifenprodil.
DB09401
The metabolism of Isosorbide can be increased when combined with Ifenprodil.
DB11507
The metabolism of Cloprostenol can be increased when combined with Ifenprodil.
DB11619
The metabolism of Gestrinone can be increased when combined with Ifenprodil.
DB11636
The metabolism of Nomegestrol can be increased when combined with Ifenprodil.
DB12025
The metabolism of Triptolide can be increased when combined with Ifenprodil.
DB12474
The metabolism of Lynestrenol can be increased when combined with Ifenprodil.
DB13044
The metabolism of Gossypol can be increased when combined with Ifenprodil.
DB13310
The metabolism of Ormeloxifene can be increased when combined with Ifenprodil.
DB13528
The metabolism of Chlormadinone can be increased when combined with Ifenprodil.
DB13563
The metabolism of Norgestrienone can be increased when combined with Ifenprodil.
DB13685
The metabolism of Quingestanol can be increased when combined with Ifenprodil.
DB13857
The metabolism of Demegestone can be increased when combined with Ifenprodil.
DB13866
The metabolism of Etynodiol can be increased when combined with Ifenprodil.
DB13944
The metabolism of Testosterone enanthate can be increased when combined with Ifenprodil.
DB13953
The metabolism of Estradiol benzoate can be increased when combined with Ifenprodil.
DB13954
The metabolism of Estradiol cypionate can be increased when combined with Ifenprodil.
DB13956
The metabolism of Estradiol valerate can be increased when combined with Ifenprodil.
DB13981
The metabolism of Nomegestrol acetate can be increased when combined with Ifenprodil.
DB14583
The metabolism of Segesterone acetate can be increased when combined with Ifenprodil.
DB14678
The metabolism of Norethindrone enanthate can be increased when combined with Ifenprodil.
DB01611
The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Hydroxychloroquine.
DB00924
The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Ifenprodil.
DB01233
The risk or severity of sedation can be increased when Metoclopramide is combined with Ifenprodil.
DB11732
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Lasmiditan.
DB00193
The risk or severity of CNS depression can be increased when Ifenprodil is combined with Tramadol.
DB01020
Ifenprodil may increase the vasodilatory activities of Isosorbide mononitrate.
DB00246
The risk or severity of adverse effects can be increased when Ziprasidone is combined with Ifenprodil.
DB00502
The risk or severity of CNS depression can be increased when Haloperidol is combined with Ifenprodil.
DB06283
The risk or severity of CNS depression can be increased when Ziconotide is combined with Ifenprodil.
DB00472
Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.
DB12404
The risk or severity of sedation can be increased when Ifenprodil is combined with Remimazolam.
DB14881
The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Ifenprodil is combined with Oliceridine.

序列

实验性质

外部标识符

resource：ChEBI
identifier：93829
resource：PubChem Compound
identifier：3689
resource：PubChem Substance
identifier：310264919
resource：KEGG Drug
identifier：D08064
resource：ChemSpider
identifier：3561
resource：BindingDB
identifier：50083351
resource：Wikipedia
identifier：Ifenprodil
resource：ChEMBL
identifier：CHEMBL305187
resource：RxCUI
identifier：27403

外部链接

Drugs.com
http://www.drugs.com/international/ifenprodil.html

路径

目标

id:BE0000417
name:Glutamate receptor ionotropic, NMDA 2B
organism:Humans
action:antagonist
Seppala T, Stromberg C, Mattila MJ: Effects of the novel 5-hydroxytryptamine reuptake inhibitor indalpine and ethanol on psychomotor performance. Arzneimittelforschung. 1988 Jan;38(1):98-102.
Tajima N, Karakas E, Grant T, Simorowski N, Diaz-Avalos R, Grigorieff N, Furukawa H: Activation of NMDA receptors and the mechanism of inhibition by ifenprodil. Nature. 2016 Jun 2;534(7605):63-8. doi: 10.1038/nature17679. Epub 2016 May 2.
Zhu S, Paoletti P: Allosteric modulators of NMDA receptors: multiple sites and mechanisms. Curr Opin Pharmacol. 2015 Feb;20:14-23. doi: 10.1016/j.coph.2014.10.009. Epub 2014 Nov 12.
Williams K: Ifenprodil discriminates subtypes of the N-methyl-D-aspartate receptor: selectivity and mechanisms at recombinant heteromeric receptors. Mol Pharmacol. 1993 Oct;44(4):851-9.
known-action:yes
name:Glutamate receptor ionotropic, NMDA 2B
general-function:Zinc ion binding
specific-function:NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine. In concert with DAPK1 at extrasynaptic sites, acts as a central mediator for stroke damage. Its phosphorylation at Ser-1303 by DAPK1 enhances synaptic NMDA receptor channel activity inducing injurious Ca2+ influx through them, resulting in an irreversible neuronal death (By similarity).
gene-name:GRIN2B
locus:12p12
cellular-location:Cell membrane
transmembrane-regions:558-578 635-655 818-838
signal-regions:1-26
theoretical-pi:6.92
molecular-weight:166365.885
chromosome-location:12
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:4586GenAtlasGRIN2BGenBank Gene DatabaseU90278GenBank Protein Database1899202IUPHAR457UniProtKBQ13224UniProt AccessionNMDE2_HUMAN
synonyms:GluN2BGlutamate [NMDA] receptor subunit epsilon-2hNR3N-methyl D-aspartate receptor subtype 2BN-methyl-D-aspartate receptor subunit 3NMDAR2BNR2BNR3
amino-acid-sequence:>lcl|BSEQ0010288|Glutamate receptor ionotropic, NMDA 2B MKPRAECCSPKFWLVLAVLAVSGSRARSQKSPPSIGIAVILVGTSDEVAIKDAHEKDDFH HLSVVPRVELVAMNETDPKSIITRICDLMSDRKIQGVVFADDTDQEAIAQILDFISAQTL TPILGIHGGSSMIMADKDESSMFFQFGPSIEQQASVMLNIMEEYDWYIFSIVTTYFPGYQ DFVNKIRSTIENSFVGWELEEVLLLDMSLDDGDSKIQNQLKKLQSPIILLYCTKEEATYI FEVANSVGLTGYGYTWIVPSLVAGDTDTVPAEFPTGLISVSYDEWDYGLPARVRDGIAII TTAASDMLSEHSFIPEPKSSCYNTHEKRIYQSNMLNRYLINVTFEGRNLSFSEDGYQMHP KLVIILLNKERKWERVGKWKDKSLQMKYYVWPRMCPETEEQEDDHLSIVTLEEAPFVIVE SVDPLSGTCMRNTVPCQKRIVTENKTDEEPGYIKKCCKGFCIDILKKISKSVKFTYDLYL VTNGKHGKKINGTWNGMIGEVVMKRAYMAVGSLTINEERSEVVDFSVPFIETGISVMVSR SNGTVSPSAFLEPFSADVWVMMFVMLLIVSAVAVFVFEYFSPVGYNRCLADGREPGGPSF TIGKAIWLLWGLVFNNSVPVQNPKGTTSKIMVSVWAFFAVIFLASYTANLAAFMIQEEYV DQVSGLSDKKFQRPNDFSPPFRFGTVPNGSTERNIRNNYAEMHAYMGKFNQRGVDDALLS LKTGKLDAFIYDAAVLNYMAGRDEGCKLVTIGSGKVFASTGYGIAIQKDSGWKRQVDLAI LQLFGDGEMEELEALWLTGICHNEKNEVMSSQLDIDNMAGVFYMLGAAMALSLITFICEH LFYWQFRHCFMGVCSGKPGMVFSISRGIYSCIHGVAIEERQSVMNSPTATMNNTHSNILR LLRTAKNMANLSGVNGSPQSALDFIRRESSVYDISEHRRSFTHSDCKSYNNPPCEENLFS DYISEVERTFGNLQLKDSNVYQDHYHHHHRPHSIGSASSIDGLYDCDNPPFTTQSRSISK KPLDIGLPSSKHSQLSDLYGKFSFKSDRYSGHDDLIRSDVSDISTHTVTYGNIEGNAAKR RKQQYKDSLKKRPASAKSRREFDEIELAYRRRPPRSPDHKRYFRDKEGLRDFYLDQFRTK ENSPHWEHVDLTDIYKERSDDFKRDSVSGGGPCTNRSHIKHGTGDKHGVVSGVPAPWEKN LTNVEWEDRSGGNFCRSCPSKLHNYSTTVTGQNSGRQACIRCEACKKAGNLYDISEDNSL QELDQPAAPVAVTSNASTTKYPQSPTNSKAQKKNRNKLRRQHSYDTFVDLQKEEAALAPR SVSLKDKGRFMDGSPYAHMFEMSAGESTFANNKSSVPTAGHHHHNNPGGGYMLSKSLYPD RVTQNPFIPTFGDDQCLLHGSKSYFFRQPTVAGASKARPDFRALVTNKPVVSALHGAVPA RFQKDICIGNQSNPCVPNNKNPRAFNGSSNGHVYEKLSSIESDV
gene-sequence:>lcl|BSEQ0010289|Glutamate receptor ionotropic, NMDA 2B (GRIN2B) ATGAAGCCCAGAGCGGAGTGCTGTTCTCCCAAGTTCTGGTTGGTGTTGGCCGTCCTGGCC GTGTCAGGCAGCAGAGCTCGTTCTCAGAAGAGCCCCCCCAGCATTGGCATTGCTGTCATC CTCGTGGGCACTTCCGACGAGGTGGCCATCAAGGATGCCCACGAGAAAGATGATTTCCAC CATCTCTCCGTGGTACCCCGGGTGGAACTGGTAGCCATGAATGAGACCGACCCAAAGAGC ATCATCACCCGCATCTGTGATCTCATGTCTGACCGGAAGATCCAGGGGGTGGTGTTTGCT GATGACACAGACCAGGAAGCCATCGCCCAGATCCTCGATTTCATTTCAGCACAGACTCTC ACCCCCATCCTGGGCATCCACGGGGGCTCCTCTATGATAATGGCAGATAAGGATGAATCC TCCATGTTCTTCCAGTTTGGCCCATCAATTGAACAGCAAGCTTCCGTAATGCTCAACATC ATGGAAGAATATGACTGGTACATCTTTTCTATCGTCACCACCTATTTCCCTGGCTACCAG GACTTTGTAAACAAGATCCGCAGCACCATTGAGAATAGCTTTGTGGGCTGGGAGCTAGAG GAGGTCCTCCTACTGGACATGTCCCTGGACGATGGAGATTCTAAGATCCAGAATCAGCTC AAGAAACTTCAAAGCCCCATCATTCTTCTTTACTGTACCAAGGAAGAAGCCACCTACATC TTTGAAGTGGCCAACTCAGTAGGGCTGACTGGCTATGGCTACACGTGGATCGTGCCCAGT CTGGTGGCAGGGGATACAGACACAGTGCCTGCGGAGTTCCCCACTGGGCTCATCTCTGTA TCATATGATGAATGGGACTATGGCCTCCCCGCCAGAGTGAGAGATGGAATTGCCATAATC ACCACTGCTGCTTCTGACATGCTGTCTGAGCACAGCTTCATCCCTGAGCCCAAAAGCAGT TGTTACAACACCCACGAGAAGAGAATCTACCAGTCCAATATGCTAAATAGGTATCTGATC AATGTCACTTTTGAGGGGAGGAATTTGTCCTTCAGTGAAGATGGCTACCAGATGCACCCG AAACTGGTGATAATTCTTCTGAACAAGGAGAGGAAGTGGGAAAGGGTGGGGAAGTGGAAA GACAAGTCCCTGCAGATGAAGTACTATGTGTGGCCCCGAATGTGTCCAGAGACTGAAGAG CAGGAGGATGACCATCTGAGCATTGTGACCCTGGAGGAGGCACCATTTGTCATTGTGGAA AGTGTGGACCCTCTGAGTGGAACCTGCATGAGGAACACAGTCCCCTGCCAAAAACGCATA GTCACTGAGAATAAAACAGACGAGGAGCCGGGTTACATCAAAAAATGCTGCAAGGGGTTC TGTATTGACATCCTTAAGAAAATTTCTAAATCTGTGAAGTTCACCTATGACCTTTACCTG GTTACCAATGGCAAGCATGGGAAGAAAATCAATGGAACCTGGAATGGTATGATTGGAGAG GTGGTCATGAAGAGGGCCTACATGGCAGTGGGCTCACTCACCATCAATGAGGAACGATCG GAGGTGGTCGACTTCTCTGTGCCCTTCATAGAGACAGGCATCAGTGTCATGGTGTCACGC AGCAATGGGACTGTCTCACCTTCTGCCTTCTTAGAGCCATTCAGCGCTGACGTATGGGTG ATGATGTTTGTGATGCTGCTCATCGTCTCAGCCGTGGCTGTCTTTGTCTTTGAGTACTTC AGCCCTGTGGGTTATAACAGGTGCCTCGCTGATGGCAGAGAGCCTGGTGGACCCTCTTTC ACCATCGGCAAAGCTATTTGGTTGCTCTGGGGTCTGGTGTTTAACAACTCCGTACCTGTG CAGAACCCAAAGGGGACCACCTCCAAGATCATGGTGTCAGTGTGGGCCTTCTTTGCTGTC ATCTTCCTGGCCAGCTACACTGCCAACTTAGCTGCCTTCATGATCCAAGAGGAATATGTG GACCAGGTTTCTGGCCTGAGCGACAAAAAGTTCCAGAGACCTAATGACTTCTCACCCCCT TTCCGCTTTGGGACCGTGCCCAACGGCAGCACAGAGAGAAATATTCGCAATAACTATGCA GAAATGCATGCCTACATGGGAAAGTTCAACCAGAGGGGTGTAGATGATGCATTGCTCTCC CTGAAAACAGGGAAACTGGATGCCTTCATCTATGATGCAGCAGTGCTGAACTATATGGCA GGCAGAGATGAAGGCTGCAAGCTGGTGACCATTGGCAGTGGGAAGGTCTTTGCTTCCACT GGCTATGGCATTGCCATCCAAAAAGATTCTGGGTGGAAGCGCCAGGTGGACCTTGCTATC CTGCAGCTCTTTGGAGATGGGGAGATGGAAGAACTGGAAGCTCTCTGGCTCACTGGCATT TGTCACAATGAGAAGAATGAGGTCATGAGCAGCCAGCTGGACATTGACAACATGGCAGGG GTCTTCTACATGTTGGGGGCGGCCATGGCTCTCAGCCTCATCACCTTCATCTGCGAACAC CTTTTCTATTGGCAGTTCCGACATTGCTTTATGGGTGTCTGTTCTGGCAAGCCTGGCATG GTCTTCTCCATCAGCAGAGGTATCTACAGCTGCATCCATGGGGTGGCGATCGAGGAGCGC CAGTCTGTAATGAACTCCCCCACCGCAACCATGAACAACACACACTCCAACATCCTGCGC CTGCTGCGCACGGCCAAGAACATGGCTAACCTGTCTGGTGTGAATGGCTCACCGCAGAGC GCCCTGGACTTCATCCGACGGGAGTCATCCGTCTATGACATCTCAGAGCACCGCCGCAGC TTCACGCATTCTGACTGCAAATCCTACAACAACCCGCCCTGTGAGGAGAACCTCTTCAGT GACTACATCAGTGAGGTAGAGAGAACGTTCGGGAACCTGCAGCTGAAGGACAGCAACGTG TACCAAGATCACTACCACCATCACCACCGGCCCCATAGTATTGGCAGTGCCAGCTCCATC GATGGGCTCTACGACTGTGACAACCCACCCTTCACCACCCAGTCCAGGTCCATCAGCAAG AAGCCCCTGGACATCGGCCTCCCCTCCTCCAAGCACAGCCAGCTCAGTGACCTGTACGGC AAATTCTCCTTCAAGAGCGACCGCTACAGTGGCCACGACGACTTGATCCGCTCCGATGTC TCTGACATCTCAACCCACACCGTCACCTATGGGAACATCGAGGGCAATGCCGCCAAGAGG CGTAAGCAGCAATATAAGGACAGCCTGAAGAAGCGGCCTGCCTCGGCCAAGTCCCGCAGG GAGTTTGACGAGATCGAGCTGGCCTACCGTCGCCGACCGCCCCGCTCCCCTGACCACAAG CGCTACTTCAGGGACAAGGAAGGGCTACGGGACTTCTACCTGGACCAGTTCCGAACAAAG GAGAACTCACCCCACTGGGAGCACGTAGACCTGACCGACATCTACAAGGAGCGGAGTGAT GACTTTAAGCGCGACTCCGTCAGCGGAGGAGGGCCCTGTACCAACAGGTCTCACATCAAG CACGGGACGGGCGACAAACACGGCGTGGTCAGCGGGGTACCTGCACCTTGGGAGAAGAAC CTGACCAACGTGGAGTGGGAGGACCGGTCCGGGGGCAACTTCTGCCGCAGCTGTCCCTCC AAGCTGCACAACTACTCCACGACGGTGACGGGTCAGAACTCGGGCAGGCAGGCGTGCATC CGGTGTGAGGCTTGCAAGAAAGCAGGCAACCTGTATGACATCAGTGAGGACAACTCCCTG CAGGAACTGGACCAGCCGGCTGCCCCAGTGGCGGTGACGTCAAACGCCTCCACCACTAAG TACCCTCAGAGCCCGACTAATTCCAAGGCCCAGAAGAAGAACCGGAACAAACTGCGCCGG CAGCACTCCTACGACACCTTCGTGGACCTGCAGAAGGAAGAAGCCGCCCTGGCCCCGCGC AGCGTAAGCCTGAAAGACAAGGGCCGATTCATGGATGGGAGCCCCTACGCCCACATGTTT GAGATGTCAGCTGGCGAGAGCACCTTTGCCAACAACAAGTCCTCAGTGCCCACTGCCGGA CATCACCACCACAACAACCCCGGCGGCGGGTACATGCTCAGCAAGTCGCTCTACCCTGAC CGGGTCACGCAAAACCCTTTCATCCCCACTTTTGGGGACGACCAGTGCTTGCTCCATGGC AGCAAATCCTACTTCTTCAGGCAGCCCACGGTGGCGGGGGCGTCGAAAGCCAGGCCGGAC TTCCGGGCCCTTGTCACCAACAAGCCGGTGGTCTCGGCCCTTCATGGGGCCGTGCCAGCC CGTTTCCAGAAGGACATCTGTATAGGGAACCAGTCCAACCCCTGTGTGCCTAACAACAAA AACCCCAGGGCTTTCAATGGCTCCAGCAATGGGCATGTTTATGAGAAACTTTCTAGTATT GAGTCTGATGTCTGA
pfams:PF01094ANF_receptorPF00060Lig_chanPF10613Lig_chan-Glu_bdPF10565NMDAR2_C
go-classifiers:componentcell junctioncomponentcell surfacecomponentintegral component of plasma membranecomponentneuron projectioncomponentneuronal postsynaptic densitycomponentNMDA selective glutamate receptor complexcomponentplasma membranecomponentpostsynaptic membranecomponentsynaptic vesiclefunctioncalcium channel activityfunctionextracellular-glutamate-gated ion channel activityfunctionglycine bindingfunctionNMDA glutamate receptor activityfunctionzinc ion bindingprocessactivation of MAPKK activityprocessaxon guidanceprocessbehavioral fear responseprocessbehavioral response to painprocessdetection of mechanical stimulus involved in sensory perception of painprocessephrin receptor signaling pathwayprocessepidermal growth factor receptor signaling pathwayprocessexcitatory postsynaptic potentialprocessFc-epsilon receptor signaling pathwayprocessfibroblast growth factor receptor signaling pathwayprocessglutamate receptor signaling pathwayprocessin utero embryonic developmentprocessinnate immune responseprocessinsulin receptor signaling pathwayprocessionotropic glutamate receptor signaling pathwayprocesslearningprocesslearning or memoryprocesslong-term synaptic potentiationprocessMAPK cascadeprocessmemoryprocessneurotrophin TRK receptor signaling pathwayprocessRas protein signal transductionprocessregulation of protein kinase A signalingprocessresponse to ethanolprocesssensory organ developmentprocesssmall GTPase mediated signal transductionprocessstartle responseprocesssuckling behaviorprocesssynaptic transmissionprocesstransportprocessvascular endothelial growth factor receptor signaling pathway
id:BE0000365
name:Glutamate receptor ionotropic, NMDA 1
organism:Humans
action:antagonist
Seppala T, Stromberg C, Mattila MJ: Effects of the novel 5-hydroxytryptamine reuptake inhibitor indalpine and ethanol on psychomotor performance. Arzneimittelforschung. 1988 Jan;38(1):98-102.
Tajima N, Karakas E, Grant T, Simorowski N, Diaz-Avalos R, Grigorieff N, Furukawa H: Activation of NMDA receptors and the mechanism of inhibition by ifenprodil. Nature. 2016 Jun 2;534(7605):63-8. doi: 10.1038/nature17679. Epub 2016 May 2.
Zhu S, Paoletti P: Allosteric modulators of NMDA receptors: multiple sites and mechanisms. Curr Opin Pharmacol. 2015 Feb;20:14-23. doi: 10.1016/j.coph.2014.10.009. Epub 2014 Nov 12.
Williams K: Ifenprodil discriminates subtypes of the N-methyl-D-aspartate receptor: selectivity and mechanisms at recombinant heteromeric receptors. Mol Pharmacol. 1993 Oct;44(4):851-9.
known-action:yes
name:Glutamate receptor ionotropic, NMDA 1
general-function:Voltage-gated cation channel activity
specific-function:NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine. This protein plays a key role in synaptic plasticity, synaptogenesis, excitotoxicity, memory acquisition and learning. It mediates neuronal functions in glutamate neurotransmission. Is involved in the cell surface targeting of NMDA receptors (By similarity).
gene-name:GRIN1
locus:9q34.3
cellular-location:Cell membrane
transmembrane-regions:560-580 637-657 813-833
signal-regions:1-18
theoretical-pi:9.2
molecular-weight:105371.945
chromosome-location:9
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:4584GenAtlasGRIN1GenBank Gene DatabaseD13515GenBank Protein Database219920IUPHAR455UniProtKBQ05586UniProt AccessionNMDZ1_HUMAN
synonyms:GluN1Glutamate [NMDA] receptor subunit zeta-1N-methyl-D-aspartate receptor subunit NR1NMD-R1NMDAR1
amino-acid-sequence:>lcl|BSEQ0000727|Glutamate receptor ionotropic, NMDA 1 MSTMRLLTLALLFSCSVARAACDPKIVNIGAVLSTRKHEQMFREAVNQANKRHGSWKIQL NATSVTHKPNAIQMALSVCEDLISSQVYAILVSHPPTPNDHFTPTPVSYTAGFYRIPVLG LTTRMSIYSDKSIHLSFLRTVPPYSHQSSVWFEMMRVYSWNHIILLVSDDHEGRAAQKRL ETLLEERESKAEKVLQFDPGTKNVTALLMEAKELEARVIILSASEDDAATVYRAAAMLNM TGSGYVWLVGEREISGNALRYAPDGILGLQLINGKNESAHISDAVGVVAQAVHELLEKEN ITDPPRGCVGNTNIWKTGPLFKRVLMSSKYADGVTGRVEFNEDGDRKFANYSIMNLQNRK LVQVGIYNGTHVIPNDRKIIWPGGETEKPRGYQMSTRLKIVTIHQEPFVYVKPTLSDGTC KEEFTVNGDPVKKVICTGPNDTSPGSPRHTVPQCCYGFCIDLLIKLARTMNFTYEVHLVA DGKFGTQERVNNSNKKEWNGMMGELLSGQADMIVAPLTINNERAQYIEFSKPFKYQGLTI LVKKEIPRSTLDSFMQPFQSTLWLLVGLSVHVVAVMLYLLDRFSPFGRFKVNSEEEEEDA LTLSSAMWFSWGVLLNSGIGEGAPRSFSARILGMVWAGFAMIIVASYTANLAAFLVLDRP EERITGINDPRLRNPSDKFIYATVKQSSVDIYFRRQVELSTMYRHMEKHNYESAAEAIQA VRDNKLHAFIWDSAVLEFEASQKCDLVTTGELFFRSGFGIGMRKDSPWKQNVSLSILKSH ENGFMEDLDKTWVRYQECDSRSNAPATLTFENMAGVFMLVAGGIVAGIFLIFIEIAYKRH KDARRKQMQLAFAAVNVWRKNLQDRKSGRAEPDPKKKATFRAITSTLASSFKRRRSSKDT STGGGRGALQNQKDTVLPRRAIEREEGQLQLCSRHRES
gene-sequence:>lcl|BSEQ0016071|Glutamate receptor ionotropic, NMDA 1 (GRIN1) ATGAGCACCATGCGCCTGCTGACGCTCGCCCTGCTGTTCTCCTGCTCCGTCGCCCGTGCC GCGTGCGACCCCAAGATCGTCAACATTGGCGCGGTGCTGAGCACGCGGAAGCACGAGCAG ATGTTCCGCGAGGCCGTGAACCAGGCCAACAAGCGGCACGGCTCCTGGAAGATTCAGCTC AATGCCACCTCCGTCACGCACAAGCCCAACGCCATCCAGATGGCTCTGTCGGTGTGCGAG GACCTCATCTCCAGCCAGGTCTACGCCATCCTAGTTAGCCATCCACCTACCCCCAACGAC CACTTCACTCCCACCCCTGTCTCCTACACAGCCGGCTTCTACCGCATACCCGTGCTGGGG CTGACCACCCGCATGTCCATCTACTCGGACAAGAGCATCCACCTGAGCTTCCTGCGCACC GTGCCGCCCTACTCCCACCAGTCCAGCGTGTGGTTTGAGATGATGCGTGTCTACAGCTGG AACCACATCATCCTGCTGGTCAGCGACGACCACGAGGGCCGGGCGGCTCAGAAACGCCTG GAGACGCTGCTGGAGGAGCGTGAGTCCAAGGCAGAGAAGGTGCTGCAGTTTGACCCAGGG ACCAAGAACGTGACGGCCCTGCTGATGGAGGCGAAAGAGCTGGAGGCCCGGGTCATCATC CTTTCTGCCAGCGAGGACGATGCTGCCACTGTATACCGCGCAGCCGCGATGCTGAACATG ACGGGCTCCGGGTACGTGTGGCTGGTCGGCGAGCGCGAGATCTCGGGGAACGCCCTGCGC TACGCCCCAGACGGCATCCTCGGGCTGCAGCTCATCAACGGCAAGAACGAGTCGGCCCAC ATCAGCGACGCCGTGGGCGTGGTGGCCCAGGCCGTGCACGAGCTCCTCGAGAAGGAGAAC ATCACCGACCCGCCGCGGGGCTGCGTGGGCAACACCAACATCTGGAAGACCGGGCCGCTC TTCAAGAGAGTGCTGATGTCTTCCAAGTATGCGGATGGGGTGACTGGTCGCGTGGAGTTC AATGAGGATGGGGACCGGAAGTTCGCCAACTACAGCATCATGAACCTGCAGAACCGCAAG CTGGTGCAAGTGGGCATCTACAATGGCACCCACGTCATCCCTAATGACAGGAAGATCATC TGGCCAGGCGGAGAGACAGAGAAGCCTCGAGGGTACCAGATGTCCACCAGACTGAAGATT GTGACGATCCACCAGGAGCCCTTCGTGTACGTCAAGCCCACGCTGAGTGATGGGACATGC AAGGAGGAGTTCACAGTCAACGGCGACCCAGTCAAGAAGGTGATCTGCACCGGGCCCAAC GACACGTCGCCGGGCAGCCCCCGCCACACGGTGCCTCAGTGTTGCTACGGCTTTTGCATC GACCTGCTCATCAAGCTGGCACGGACCATGAACTTCACCTACGAGGTGCACCTGGTGGCA GATGGCAAGTTCGGCACACAGGAGCGGGTGAACAACAGCAACAAGAAGGAGTGGAATGGG ATGATGGGCGAGCTGCTCAGCGGGCAGGCAGACATGATCGTGGCGCCGCTAACCATAAAC AACGAGCGCGCGCAGTACATCGAGTTTTCCAAGCCCTTCAAGTACCAGGGCCTGACTATT CTGGTCAAGAAGGAGATTCCCCGGAGCACGCTGGACTCGTTCATGCAGCCGTTCCAGAGC ACACTGTGGCTGCTGGTGGGGCTGTCGGTGCACGTGGTGGCCGTGATGCTGTACCTGCTG GACCGCTTCAGCCCCTTCGGCCGGTTCAAGGTGAACAGCGAGGAGGAGGAGGAGGACGCA CTGACCCTGTCCTCGGCCATGTGGTTCTCCTGGGGCGTCCTGCTCAACTCCGGCATCGGG GAAGGCGCCCCCAGAAGCTTCTCAGCGCGCATCCTGGGCATGGTGTGGGCCGGCTTTGCC ATGATCATCGTGGCCTCCTACACCGCCAACCTGGCGGCCTTCCTGGTGCTGGACCGGCCG GAGGAGCGCATCACGGGCATCAACGACCCTCGGCTGAGGAACCCCTCGGACAAGTTTATC TACGCCACGGTGAAGCAGAGCTCCGTGGATATCTACTTCCGGCGCCAGGTGGAGCTGAGC ACCATGTACCGGCATATGGAGAAGCACAACTACGAGAGTGCGGCGGAGGCCATCCAGGCC GTGAGAGACAACAAGCTGCATGCCTTCATCTGGGACTCGGCGGTGCTGGAGTTCGAGGCC TCGCAGAAGTGCGACCTGGTGACGACTGGAGAGCTGTTTTTCCGCTCGGGCTTCGGCATA GGCATGCGCAAAGACAGCCCCTGGAAGCAGAACGTCTCCCTGTCCATCCTCAAGTCCCAC GAGAATGGCTTCATGGAAGACCTGGACAAGACGTGGGTTCGGTATCAGGAATGTGACTCG CGCAGCAACGCCCCTGCGACCCTTACTTTTGAGAACATGGCCGGGGTCTTCATGCTGGTA GCTGGGGGCATCGTGGCCGGGATCTTCCTGATTTTCATCGAGATTGCCTACAAGCGGCAC AAGGATGCTCGCCGGAAGCAGATGCAGCTGGCCTTTGCCGCCGTTAACGTGTGGCGGAAG AACCTGCAGCAGTACCATCCCACTGATATCACGGGCCCGCTCAACCTCTCAGATCCCTCG GTCAGCACCGTGGTGTGA
pfams:PF01094ANF_receptorPF00060Lig_chanPF10613Lig_chan-Glu_bdPF10562CaM_bdg_C0
go-classifiers:componentcell junctioncomponentcell surfacecomponentdendritecomponentdendrite membranecomponentdendritic branchcomponentdendritic spinecomponentendoplasmic reticulumcomponentexcitatory synapsecomponentintegral component of plasma membranecomponentneuron projectioncomponentneuronal cell bodycomponentneuronal postsynaptic densitycomponentNMDA selective glutamate receptor complexcomponentplasma membranecomponentpostsynaptic densitycomponentpostsynaptic membranecomponentsynapsecomponentsynaptic cleftcomponentsynaptic vesiclecomponentterminal boutonfunctioncalcium channel activityfunctioncalcium ion bindingfunctioncalmodulin bindingfunctionextracellular-glutamate-gated ion channel activityfunctionglutamate bindingfunctionglycine bindingfunctionneurotransmitter bindingfunctionNMDA glutamate receptor activityfunctionvoltage-gated cation channel activityprocessactivation of MAPKK activityprocessadult locomotory behaviorprocessaxon guidanceprocesscalcium ion homeostasisprocesscalcium ion transmembrane transportprocesscation transportprocesscellular calcium ion homeostasisprocesscellular response to manganese ionprocesscerebral cortex developmentprocessconditioned taste aversionprocessephrin receptor signaling pathwayprocessepidermal growth factor receptor signaling pathwayprocessexcitatory postsynaptic potentialprocessFc-epsilon receptor signaling pathwayprocessfibroblast growth factor receptor signaling pathwayprocessinnate immune responseprocessinsulin receptor signaling pathwayprocession transmembrane transportprocessionotropic glutamate receptor signaling pathwayprocesslong-term memoryprocessmale mating behaviorprocessMAPK cascadeprocessnegative regulation of neuron apoptotic processprocessneurotrophin TRK receptor signaling pathwayprocessolfactory learningprocesspons maturationprocesspositive regulation of apoptotic processprocesspositive regulation of excitatory postsynaptic potentialprocesspositive regulation of transcription from RNA polymerase II promoterprocessprepulse inhibitionprocesspropylene metabolic processprocessprotein tetramerizationprocessRas protein signal transductionprocessregulation of axonogenesisprocessregulation of dendrite morphogenesisprocessregulation of long-term neuronal synaptic plasticityprocessregulation of membrane potentialprocessregulation of respiratory gaseous exchangeprocessregulation of synapse assemblyprocessrespiratory gaseous exchangeprocessresponse to amphetamineprocessresponse to calcium ionprocessresponse to ethanolprocessresponse to fungicideprocessresponse to morphineprocessrhythmic processprocesssensory perception of painprocesssmall GTPase mediated signal transductionprocesssocial behaviorprocesssuckling behaviorprocesssynaptic transmissionprocesssynaptic transmission, glutamatergicprocessvascular endothelial growth factor receptor signaling pathwayprocessvisual learning
id:BE0001028
name:G protein-activated inward rectifier potassium channel 1
organism:Humans
action:antagonist
Kobayashi T, Washiyama K, Ikeda K: Inhibition of G protein-activated inwardly rectifying K+ channels by ifenprodil. Neuropsychopharmacology. 2006 Mar;31(3):516-24. doi: 10.1038/sj.npp.1300844.
known-action:unknown
name:G protein-activated inward rectifier potassium channel 1
general-function:G-protein activated inward rectifier potassium channel activity
specific-function:This potassium channel is controlled by G proteins. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward rectification is mainly due to the blockage of outward current by internal magnesium. This receptor plays a crucial role in regulating the heartbeat.
gene-name:KCNJ3
locus:2q24.1
cellular-location:Membrane
transmembrane-regions:81-105 158-179
signal-regions:
theoretical-pi:8.36
molecular-weight:56602.84
chromosome-location:2
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:6264GenAtlasKCNJ3GenBank Gene DatabaseU39196GenBank Protein Database1055028IUPHAR434Guide to Pharmacology434UniProtKBP48549UniProt AccessionKCNJ3_HUMAN
synonyms:GIRK-1GIRK1Inward rectifier K(+) channel Kir3.1Potassium channel, inwardly rectifying subfamily J member 3
amino-acid-sequence:>lcl|BSEQ0002047|G protein-activated inward rectifier potassium channel 1 MSALRRKFGDDYQVVTTSSSGSGLQPQGPGQDPQQQLVPKKKRQRFVDKNGRCNVQHGNL GSETSRYLSDLFTTLVDLKWRWNLFIFILTYTVAWLFMASMWWVIAYTRGDLNKAHVGNY TPCVANVYNFPSAFLFFIETEATIGYGYRYITDKCPEGIILFLFQSILGSIVDAFLIGCM FIKMSQPKKRAETLMFSEHAVISMRDGKLTLMFRVGNLRNSHMVSAQIRCKLLKSRQTPE GEFLPLDQLELDVGFSTGADQLFLVSPLTICHVIDAKSPFYDLSQRSMQTEQFEIVVILE GIVETTGMTCQARTSYTEDEVLWGHRFFPVISLEEGFFKVDYSQFHATFEVPTPPYSVKE QEEMLLMSSPLIAPAITNSKERHNSVECLDGLDDITTKLPSKLQKITGREDFPKKLLRMS STTSEKAYSLGDLPMKLQRISSVPGNSEEKLVSKTTKMLSDPMSQSVADLPPKLQKMAGG AARMEGNLPAKLRKMNSDRFT
gene-sequence:>lcl|BSEQ0010718|G protein-activated inward rectifier potassium channel 1 (KCNJ3) ATGTCTGCACTCCGAAGGAAATTTGGGGACGATTATCAGGTAGTGACCACATCGTCCAGC GGCTCGGGCTTGCAGCCCCAGGGGCCAGGCCAGGACCCTCAGCAGCAGCTTGTGCCCAAG AAGAAGCGGCAGCGGTTCGTGGACAAGAACGGCCGGTGCAATGTACAGCACGGCAACCTG GGCAGCGAGACAAGCCGCTACCTCTCGGACCTCTTCACCACGCTGGTGGACCTCAAGTGG CGCTGGAACCTCTTCATCTTCATTCTCACCTACACCGTGGCCTGGCTTTTCATGGCGTCC ATGTGGTGGGTGATCGCCTACACTCGGGGCGACCTGAACAAAGCCCACGTCGGTAACTAC ACGCCTTGCGTGGCCAATGTCTATAACTTCCCTTCTGCCTTCCTCTTCTTCATCGAGACG GAGGCCACCATCGGCTATGGCTACCGATACATCACAGACAAGTGCCCCGAGGGCATCATC CTCTTCCTCTTCCAGTCCATCCTGGGCTCCATCGTGGACGCCTTCCTCATCGGCTGCATG TTCATCAAGATGTCCCAGCCCAAGAAGCGCGCCGAGACCCTCATGTTCAGCGAGCACGCG GTGATCTCCATGAGGGACGGAAAACTCACGCTTATGTTCCGGGTGGGCAACCTGCGCAAC AGCCACATGGTCTCCGCGCAGATTCGCTGCAAGCTGCTCAAAGGATGA
pfams:PF01007IRK
go-classifiers:componentexternal side of plasma membranecomponentintegral component of plasma membranecomponentplasma membranecomponentT-tubulecomponentvoltage-gated potassium channel complexfunctionG-protein activated inward rectifier potassium channel activityprocesspotassium ion importprocesspotassium ion transportprocessregulation of ion transmembrane transportprocessresponse to electrical stimulusprocesssynaptic transmission
id:BE0001030
name:G protein-activated inward rectifier potassium channel 2
organism:Humans
action:antagonist
Kobayashi T, Washiyama K, Ikeda K: Inhibition of G protein-activated inwardly rectifying K+ channels by ifenprodil. Neuropsychopharmacology. 2006 Mar;31(3):516-24. doi: 10.1038/sj.npp.1300844.
known-action:unknown
name:G protein-activated inward rectifier potassium channel 2
general-function:Inward rectifier potassium channel activity
specific-function:This potassium channel may be involved in the regulation of insulin secretion by glucose and/or neurotransmitters acting through G-protein-coupled receptors. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward rectification is mainly due to the blockage of outward current by internal magnesium.
gene-name:KCNJ6
locus:
cellular-location:Membrane
transmembrane-regions:90-114 167-188
signal-regions:
theoretical-pi:5.04
molecular-weight:48450.96
chromosome-location:21
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:6267GenAtlasKCNJ6GenBank Gene DatabaseU24660GenBank Protein Database1052875IUPHAR435Guide to Pharmacology435UniProtKBP48051UniProt AccessionKCNJ6_HUMAN
synonyms:BIR1GIRK-2GIRK2Inward rectifier K(+) channel Kir3.2KATP-2KATP2KCNJ7Potassium channel, inwardly rectifying subfamily J member 6
amino-acid-sequence:>lcl|BSEQ0010719|G protein-activated inward rectifier potassium channel 2 MAKLTESMTNVLEGDSMDQDVESPVAIHQPKLPKQARDDLPRHISRDRTKRKIQRYVRKD GKCNVHHGNVRETYRYLTDIFTTLVDLKWRFNLLIFVMVYTVTWLFFGMIWWLIAYIRGD MDHIEDPSWTPCVTNLNGFVSAFLFSIETETTIGYGYRVITDKCPEGIILLLIQSVLGSI VNAFMVGCMFVKISQPKKRAETLVFSTHAVISMRDGKLCLMFRVGDLRNSHIVEASIRAK LIKSKQTSEGEFIPLNQTDINVGYYTGDDRLFLVSPLIISHEINQQSPFWEISKAQLPKE ELEIVVILEGMVEATGMTCQARSSYITSEILWGYRFTPVLTLEDGFYEVDYNSFHETYET STPSLSAKELAELASRAELPLSWSVSSKLNQHAELETEEEEKNLEEQTERNGDVANLENE SKV
gene-sequence:>lcl|BSEQ0010720|G protein-activated inward rectifier potassium channel 2 (KCNJ6) ATGGCCAAGCTGACAGAATCCATGACTAACGTCCTGGAGGGCGACTCCATGGATCAGGAC GTCGAAAGCCCAGTGGCCATTCACCAGCCAAAGTTGCCTAAGCAGGCCAGGGATGACCTG CCAAGACACATCAGCCGAGATCGGACCAAAAGGAAAATCCAGAGGTACGTGAGGAAAGAC GGAAAGTGCAATGTTCATCACGGCAACGTGAGGGAGACCTATCGCTACCTGACCGATATC TTCACCACATTAGTGGACCTGAAGTGGAGATTCAACCTATTGATTTTTGTCATGGTTTAC ACAGTGACCTGGCTCTTTTTTGGAATGATCTGGTGGTTGATCGCATACATACGGGGAGAC ATGGACCACATAGAGGACCCCTCCTGGACTCCTTGTGTTACCAACCTCAACGGGTTCGTC TCTGCTTTTTTATTCTCAATAGAGACAGAAACCACCATTGGTTATGGCTACCGGGTCATC ACAGATAAATGCCCAGAGGGAATTATTCTTCTCTTAATCCAATCTGTGTTGGGGTCCATT GTCAATGCATTCATGGTGGGATGCATGTTTGTAAAAATCTCTCAACCCAAGAAGAGGGCA GAGACCCTGGTCTTTTCCACCCATGCAGTGATCTCCATGCGGGATGGGAAACTGTGCCTG ATGTTCCGGGTAGGGGACCTTAGGAATTCCCACATTGTGGAGGCTTCCATCAGAGCCAAG TTGATCAAATCCAAACAGACCTCGGAGGGGGAGTTCATCCCGTTGAACCAGACGGATATC AACGTAGGGTATTACACGGGGGATGACCGTCTGTTTCTGGTGTCACCGCTGATCATTAGC CATGAAATTAACCAACAGAGTCCTTTCTGGGAGATCTCCAAAGCCCAGCTGCCCAAAGAG GAACTGGAAATTGTGGTCATCCTAGAAGGAATGGTGGAAGCCACAGGGATGACATGCCAA GCTCGAAGCTCCTACATCACCAGTGAGATCCTGTGGGGTTACCGGTTCACACCTGTCCTG ACCCTGGAGGACGGGTTCTACGAAGTTGACTACAACAGCTTCCATGAGACCTATGAGACC AGCACCCCATCCCTTAGTGCCAAAGAGCTGGCCGAGTTAGCCAGCAGGGCAGAGCTGCCC CTGAGTTGGTCTGTATCCAGCAAACTCAACCAACATGCAGAACTGGAGACTGAAGAGGAA GAAAAGAACCTCGAAGAGCAAACAGAAAGAAATGGTGATGTGGCAAACCTGGAGAATGAA TCCAAAGTTTAG
pfams:PF01007IRK
go-classifiers:componentGolgi apparatuscomponentintegral component of plasma membranecomponentplasma membranecomponentvoltage-gated potassium channel complexfunctionG-protein activated inward rectifier potassium channel activityfunctioninward rectifier potassium channel activityprocesspotassium ion importprocesspotassium ion transportprocessregulation of ion transmembrane transportprocesssynaptic transmission
id:BE0002218
name:G protein-activated inward rectifier potassium channel 4
organism:Humans
action:antagonist
Kobayashi T, Washiyama K, Ikeda K: Inhibition of G protein-activated inwardly rectifying K+ channels by ifenprodil. Neuropsychopharmacology. 2006 Mar;31(3):516-24. doi: 10.1038/sj.npp.1300844.
known-action:unknown
name:G protein-activated inward rectifier potassium channel 4
general-function:G-protein activated inward rectifier potassium channel activity
specific-function:This potassium channel is controlled by G proteins. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward rectification is mainly due to the blockage of outward current by internal magnesium. Can be blocked by external barium.
gene-name:KCNJ5
locus:11q24
cellular-location:Membrane
transmembrane-regions:87-111 164-185
signal-regions:
theoretical-pi:4.96
molecular-weight:47667.3
chromosome-location:11
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:6266GenAtlasKCNJ5GenBank Gene DatabaseU39195GenBank Protein Database1055026IUPHAR437Guide to Pharmacology437UniProtKBP48544UniProt AccessionKCNJ5_HUMAN
synonyms:Cardiac inward rectifierCIRGIRK-4GIRK4Heart KATP channelInward rectifier K(+) channel Kir3.4IRK-4KATP-1Potassium channel, inwardly rectifying subfamily J member 5
amino-acid-sequence:>lcl|BSEQ0011601|G protein-activated inward rectifier potassium channel 4 MAGDSRNAMNQDMEIGVTPWDPKKIPKQARDYVPIATDRTRLLAEGKKPRQRYMEKSGKC NVHHGNVQETYRYLSDLFTTLVDLKWRFNLLVFTMVYTVTWLFFGFIWWLIAYIRGDLDH VGDQEWIPCVENLSGFVSAFLFSIETETTIGYGFRVITEKCPEGIILLLVQAILGSIVNA FMVGCMFVKISQPKKRAETLMFSNNAVISMRDEKLCLMFRVGDLRNSHIVEASIRAKLIK SRQTKEGEFIPLNQTDINVGFDTGDDRLFLVSPLIISHEINQKSPFWEMSQAQLHQEEFE VVVILEGMVEATGMTCQARSSYMDTEVLWGHRFTPVLTLEKGFYEVDYNTFHDTYETNTP SCCAKELAEMKREGRLLQYLPSPPLLGGCAEAGLDAEAEQNEEDEPKGLGGSREARGSV
gene-sequence:>lcl|BSEQ0011602|G protein-activated inward rectifier potassium channel 4 (KCNJ5) ATGGCTGGCGATTCTAGGAATGCCATGAACCAGGACATGGAGATTGGAGTCACTCCCTGG GACCCCAAGAAGATTCCAAAACAGGCCCGCGATTATGTCCCCATTGCCACAGACCGTACG CGCCTGCTGGCCGAGGGCAAGAAGCCACGCCAGCGCTACATGGAGAAGAGTGGCAAGTGC AACGTGCACCACGGCAACGTCCAGGAGACCTACCGGTACCTGAGTGACCTCTTCACCACC CTGGTGGACCTCAAGTGGCGCTTCAACTTGCTCGTCTTCACCATGGTTTACACTGTCACC TGGCTGTTCTTCGGCTTCATTTGGTGGCTCATTGCTTATATCCGGGGTGACCTGGACCAT GTTGGCGACCAAGAGTGGATTCCTTGTGTTGAAAACCTCAGTGGCTTCGTGTCCGCTTTC CTGTTCTCCATTGAGACCGAAACAACCATTGGGTATGGCTTCCGAGTCATCACAGAGAAG TGTCCAGAGGGGATTATACTCCTCTTGGTCCAGGCCATCCTGGGCTCCATCGTCAATGCC TTCATGGTGGGGTGCATGTTTGTCAAGATCAGCCAGCCCAAGAAGAGAGCGGAGACCCTC ATGTTTTCCAACAACGCAGTCATCTCCATGCGGGACGAGAAGCTGTGCCTCATGTTCCGG GTGGGCGACCTCCGCAACTCCCACATCGTGGAGGCCTCCATCCGGGCCAAGCTCATCAAG TCCCGGCAGACCAAAGAGGGGGAGTTCATCCCCCTGAACCAGACAGACATCAACGTGGGC TTTGACACGGGCGACGACCGCCTCTTCCTTGTGTCTCCTCTGATCATCTCCCATGAGATC AACCAGAAGAGCCCTTTCTGGGAGATGTCTCAGGCTCAGCTGCATCAGGAAGAGTTTGAA GTTGTGGTCATTCTAGAAGGGATGGTGGAAGCCACAGGCATGACCTGCCAAGCCCGGAGC TCCTACATGGATACAGAGGTGCTCTGGGGCCACCGATTCACACCAGTCCTCACCTTGGAA AAGGGCTTCTATGAGGTGGACTACAACACCTTCCATGATACCTATGAGACCAACACACCC AGCTGCTGTGCCAAGGAGCTGGCAGAAATGAAGAGGGAAGGCCGGCTCCTCCAGTACCTC CCCAGCCCCCCACTGCTGGGGGGCTGTGCTGAGGCAGGGCTGGATGCAGAGGCTGAGCAG AATGAAGAAGATGAGCCCAAGGGGCTGGGTGGGTCCAGGGAGGCCAGGGGCTCGGTGTGA
pfams:PF01007IRK
go-classifiers:componentexternal side of plasma membranecomponentintegral component of plasma membranecomponentplasma membranecomponentT-tubulecomponentvoltage-gated potassium channel complexfunctionG-protein activated inward rectifier potassium channel activityprocesspotassium ion importprocesspotassium ion transportprocessregulation of ion transmembrane transportprocesssynaptic transmission

酶

载体

运输工具

药物反应

效应

不良反应